

SUPPORTING INFORMATION

Synthesis of Highly Enantioenriched 3,4-Dihydroquinolin-2-ones by 6-*Exo-trig* Radical Cyclizations of Axially Chiral α -Halo-*o*-Alkenyl Anilides

David B. Guthrie, Stephen J. Geib and Dennis P. Curran

Department of Chemistry, University of Pittsburgh, Pittsburgh PA, 15260

email: curran@pitt.edu

Table of Contents

| | |
|---|----|
| GENERAL METHODS | 2 |
| <i>N</i> -SUBSTITUTION OF <i>O</i> -IODOANILINES | 5 |
| INSTALLATION OF RADICAL ACCEPTOR GROUPS | 11 |
| PREPARATION OF ALPHA-HALOACETAMIDE PRECURSORS | 20 |
| RADICAL CYCLIZATIONS OF SUBSTRATES | 40 |
| SYNTHESIS OF OTHER COMPOUNDS..... | 51 |
| ANALYSIS OF <i>N</i> -ARYL BOND ROTATION BARRIERS | 54 |
| REFERENCES | 59 |
| COPIES OF SPECTRA | 60 |

General Methods

All reactions were performed in oven-dried glassware under an argon atmosphere, except where noted. Chemicals and solvents were purchased from commercial suppliers and used as received, excepting as follows. Dichloromethane, THF, ether, and toluene were dried by passing through an activated alumina column. When necessary, benzene was degassed by the freeze-pump-thaw method (at least 5 cycles). Trimethylsilyl chloride (TMSCl) was distilled over CaH₂ before use. Solutions of BuLi were titrated regularly against diphenylacetic acid in THF.

All reactions were followed by TLC to completion, unless stated otherwise. TLC analysis was performed by illumination with a UV lamp (254 nm) or staining with KMnO₄ and heating. All flash chromatography was performed with 230-400 mesh silica gel purchased from Sorbent Technologies as the stationary phase. “Gradient column chromatography” refers to packing the column with the initial eluent, and initially filling the solvent reservoir with ~4 column volumes of the initial eluent. After elution of one column volume, the solvent reservoir is refilled with the second eluent. This process is continued after every eluted column volume until the final compound has completely eluted.

¹H NMR spectra were measured on a Bruker Avance 300 MHz instrument in CDCl₃, and chemical shifts were measured relative to residual solvent peak (δ 7.27). The following abbreviations were used to describe coupling: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. ¹³C NMR spectra were measured on Bruker Avance instruments at 75 MHz with chemical shifts relative to residual solvent peak (δ 77.0). In ¹³C spectra, a notation of (xC) is used to denote *x* equivalent carbons for a multi-carbon signal. IR spectra were recorded

as thin films (CHCl₃) or neat on NaCl plates on an ATI Mattson Genesis Series FTIR spectrometer. All quoted optical rotation values are corrected for 100% ee samples.

Melting ranges were determined using a Mel-Temp II apparatus and are uncorrected. Compounds listed as having a melting point at a single temperature had a sharp melting range of < 0.5 °C. Optical rotations were measured on a Perkin-Elmer 241 Polarimeter using a 1 dm cell length. All quoted optical rotation values are corrected for 100% ee samples, and have the units (deg cm² g⁻¹). Mass spectra were obtained on a VG-7070 or Fisons Autospec high-resolution magnetic sector mass spectrometer.

Analytical chiral HPLC analysis was conducted using either an (*S,S*)-Whelk-O 1 column (Pirkle, 250 mm x 4.6 mm ID) or a Chiralcel OD column (Daicel, 250 mm x 4.6 mm ID) typically eluting with hexanes:*i*-PrOH at 1.0 mL/min, 10-20 µg per injection. Preparatory chiral HPLC resolutions were performed on either an (*S,S*)-Whelk-O 1 column (Pirkle, 25 cm x 21.1 mm ID) or a Chiralcel OD column (Daicel, 250 mm x 20.0 mm ID) eluting with hexanes:*i*PrOH at 10.0 mL/min, 40-150 mg per injection. All HPLC injections were monitored with a Waters model 440 UV detector at wavelength 254 nm, when the solvent system was hexane:*i*-PrOH. In the cases where a hexane:EtOAc solvent system was used, the injections were monitored at wavelength 270 nm.

Gas chromatography analysis was performed with an Agilent 6850 GC under the following conditions: Initial oven temp. 100 °C, first ramp 10 °C/min to 250 °C, second ramp 15 °C/min to 315 °C, held at this temperature for 8 min. All GC yields were determined by calculation of response factors, using a straight-chain alkane internal standard. For each compound analyzed, three standard mixtures of a measured amount of the compound and a

known amount of internal standard from a stock solution were analyzed by GC. Response factors were calculated using the equation:¹

$$RF_X = \frac{M_{IS} \cdot A_X}{A_{IS} \cdot M_X}$$

RF_X = response factor of compound X



M_{IS} = moles of internal standard

M_X = moles of compound X

A_{IS} = area of internal standard GC peak


A_X = area of compound X GC peak

For each compound X, the three trials were graphed with the M_{IS}/M_X value on the y-axis, and the corresponding A_{IS}/A_X value on the x-axis. The slope of the line was taken to be the RF_X value. All compounds gave excellent linear plots with intercepts ≈ 0 , showing that the response factor for each compound was consistent over varying molar ratios of compound to internal standard.

***N*-Substitution of *o*-Iodoanilines****Scheme S.1 Preparation of *N*-Substituted Anilines**


2-Iodo-*N*-4,6-trimethylaniline (17): LDA was made by dissolving *N,N*-diisopropylamine (2.43 g, 24.0 mmol) in THF (10 mL) at $-78\text{ }^{\circ}\text{C}$ with stirring, and adding a hexanes solution of BuLi (15.7 mL, 22.0 mmol) dropwise. The reaction mixture was stirred at this temperature for 40 min, warmed to $0\text{ }^{\circ}\text{C}$ and stirred for 10 min. The resulting solution of LDA was then added dropwise over 10 min to a stirred solution of 2-iodo-4,6-dimethylaniline^{2,3} (4.94 g, 20.0 mmol) in THF (150 mL) at $-78\text{ }^{\circ}\text{C}$, and the mixture was stirred for an additional 20 min. Methyl iodide (2.98 g, 21.0 mmol) was added dropwise via syringe, the reaction mixture was warmed to room

temperature, and stirred for 1 h. The mixture was quenched with saturated aqueous NH₄Cl solution (200 mL) and diluted with Et₂O (250 mL). The organic layer was separated and washed with saturated aqueous NH₄Cl (3 x 250 mL) and brine (250 mL) solutions, dried over MgSO₄, filtered, and concentrated by rotary evaporation. Flash chromatography (25:1 pentane:Et₂O) afforded the title compound (4.40 g, 84%) as a red-brown, acrid-smelling liquid: ¹H NMR (300 MHz, CDCl₃) δ 7.44 (s, 1H), 6.93 (s, 1H), 3.31 (br s, 1H), 2.73 (s, 3H), 2.35 (s, 3H), 2.22 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 146.8, 136.8, 133.6, 132.5, 130.8, 95.3, 35.3, 19.9, 19.5; FTIR (neat, cm⁻¹) 3348, 2949, 2917, 2860, 1481, 1411, 1277, 1108, 1028, 852, 790, 726; LRMS (EI) *m/z* 261 (M⁺, 75), 246 (32), 134 (29), 118 (27), 105 (45), 91 (100), 78 (87), 76 (99); HRMS (EI) calcd for C₉H₁₂IN: 261.0015, found: 261.0019.




2-Iodo-N-(4-methoxybenzyl)-4,6-dimethylaniline (S1): To a stirred solution of 2-iodo-4,6-dimethylaniline^{2,3} (6.18 g, 25.0 mmol) and *p*-anisaldehyde (3.57 g, 26.3 mmol) in EtOAc (75 mL) was added trifluoroacetic acid (5.70 g, 50.0 mmol). The mixture was stirred at room temperature for 30 min, and solid NaBH(OAc)₃ (9.54 g, 45.0 mmol) was added portionwise over 5 min. The reaction mixture was stirred for 3 h, cooled to 0 °C, and quenched with 10% w/w aqueous NaOH solution (*very* slowly at first, until gas production stopped) until two distinct layers formed. The organic layer was separated and washed with brine (2 x 100 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (10:1 hexanes:EtOAc) afforded the title compound (7.59 g, 83%) as an off-white solid, mp 69-70 °C:

^1H NMR (300 MHz, CDCl_3) δ 7.47 (s, 1H), 7.36 (d, $J = 8.7$ Hz, 2H), 6.95 (s, 1H), 6.90 (d, $J = 8.7$ Hz, 2H), 4.02 (s, 2H), 3.83 (s, 3H), 3.44 (br s, 1H), 2.37 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 158.7, 145.2, 137.0, 133.9, 132.3, 131.6, 131.3, 129.3 (2C), 113.7 (2C), 96.2, 55.0, 52.1, 19.9, 19.4; FTIR (thin film, CHCl_3 , cm^{-1}) 3326, 2928, 2832, 1509, 1471, 1462, 1275, 1179, 1055, 1029, 831, 820, 738; LRMS (EI) m/z 368 (26), 367 (M^+ , 82), 238 (37), 122 (65), 121 (100), 91 (32), 77 (40); HRMS (EI) calcd for $\text{C}_{16}\text{H}_{18}\text{INO}$: 367.0433, found: 367.0430.




2-Iodo-6-methoxy-N-(4-methoxybenzyl)aniline (S2): To a stirred solution of *t*-butyl 2-iodo-6-methoxyphenylcarbamate⁴ (4.36 g, 12.5 mmol) in CH_2Cl_2 (60 mL) at 0 °C was added trifluoroacetic acid (14.25 g, 125 mmol) in one portion via syringe. The reaction mixture was warmed to room temperature and stirred for 1.5 h, at which time *p*-anisaldehyde (1.79 g, 13.1 mmol) was added in one portion via syringe. The reaction was stirred for 10 min, and solid $\text{NaBH}(\text{OAc})_3$ (7.95 g, 37.5 mmol) was added portionwise over 10 min. The mixture was stirred for 1 h, cooled to 0 °C, and quenched (*very* slowly at first, until gas production stopped) with 10% w/w aqueous NaOH solution (50 mL). The organic layer was separated and washed with brine (50 mL), dried over MgSO_4 , filtered, and concentrated by rotary evaporation. Column chromatography (6:1 pentane: Et_2O) afforded the title compound (3.36 g, 76%) as a yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 7.35 (dd, $J = 8.1$ Hz, 1.2 Hz, 1H), 7.30 (d, $J = 8.7$ Hz, 2H), 6.86 (d, $J = 8.7$ Hz, 2H), 6.81 (dd, $J = 8.1$ Hz, 1.2 Hz, 1H), 6.64 (t, $J = 8.1$ Hz, 1H), 4.32 (s, 2H), 4.02 (br s, 1H), 3.82 (s, 3H), 3.81 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 158.6, 151.2, 139.0, 132.1, 131.2 (2C), 129.3, 123.1, 113.6 (2C), 111.4, 92.3, 55.7, 55.1, 51.4; FTIR (neat, cm^{-1}) 3347, 2934,


2833, 1611, 1582, 1512, 1463, 1247, 1175, 1031, 830, 760, 726; LRMS (EI) m/z 369 (M^+ , 25), 240 (5), 121 (100), 91 (6), 77 (7); HRMS (EI) calcd for $C_{15}H_{16}INO_2$: 369.0226, found: 369.0227.



***N*-(2-Iodo-4,6-dimethylphenyl)-4-methylbenzenesulfonamide (S3):** To a stirred solution of 2-iodo-4,6-dimethylaniline^{2,3} (2.47 g, 10.0 mmol) in pyridine (10 mL) was added *p*-toluenesulfonyl chloride (2.29 g, 12.0 mmol) all at once. The reaction mixture was stirred at room temperature for 5 h, at which point saturated aqueous NH_4Cl solution (40 mL) was added to quench the reaction. The mixture was extracted with CH_2Cl_2 (4 x 40 mL), and the combined organic layers were washed with 1 N HCl (3 x 40 mL) and brine (3 x 40 mL), dried over $MgSO_4$, filtered, and concentrated by rotary evaporation. Column chromatography (4:1 hexanes:EtOAc) afforded the title compound (3.63 g, 90%) as a white solid, mp 157-158 °C: 1H NMR (300 MHz, $CDCl_3$) δ 7.56 (d, $J = 8.1$ Hz, 2H), 7.39 (s, 1H), 7.25 (d, $J = 8.1$ Hz, 2H), 7.07 (s, 1H), 6.04 (s, 1H), 2.49 (s, 3H), 2.44 (s, 3H), 2.26 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 143.9, 139.4, 139.2, 137.5, 137.2, 133.2, 132.7, 129.5 (2C), 127.9 (2C), 100.2, 21.6, 20.7, 20.3; FTIR (thin film, $CHCl_3$, cm^{-1}) 3270 (broad), 2922, 1598, 1465, 1387, 1330, 1162, 1091, 891, 813, 756, 709; HRMS (ESI) calcd for $C_{15}H_{16}INNaO_2S$ [$M + Na$]⁺: 423.9844, found: 423.9849.




2-Iodo-N-(4-methoxybenzyl)-4-methyl-6-(trimethylsilyl)aniline (S4): To a stirred solution of 2-iodo-4-methyl-6-(trimethylsilyl)aniline³ (5.26 g, 17.2 mmol) in THF (85 mL) at -78 °C was added a hexanes solution of LiHMDS (19.0 mL, 19.0 mmol) dropwise via syringe. The reaction mixture was warmed to room temperature, stirred for 30 min, and recooled to -78 °C. A solution of 4-methoxybenzyl bromide (4.16 g, 20.7 mmol) in THF (15 mL) was added to the reaction mixture dropwise via syringe, the mixture was warmed to room temperature and stirred for 3 h. Saturated aqueous NH_4Cl solution (100 mL) was added, and the mixture was extracted with Et_2O (3 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO_4 , filtered, and concentrated by rotary evaporation. Column chromatography (98:2 pentane: Et_2O) furnished the title compound (5.94 g, 81%) as an orange oil: ^1H NMR (300 MHz, CDCl_3) δ 7.71 (dd, $J = 1.8$ Hz, 0.6 Hz, 1H), 7.44 (d, $J = 8.7$ Hz, 2H), 7.24 (d, $J = 1.5$ Hz, 1H), 6.92 (d, $J = 8.7$ Hz, 2H), 4.05 (d, $J = 6.9$ Hz, 2 H), 3.84 (s, 3H), 3.26 (br t, $J = 6.9$ Hz, 1H), 2.29 (s, 3H), 0.34 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 158.8, 151.7, 141.3, 136.6, 136.2, 134.9, 131.6, 129.1 (2C), 113.8 (2C), 98.9, 55.2, 54.6, 20.2, 0.4 (3C); FTIR (neat, cm^{-1}) 3297, 2952, 2899, 2833, 1611, 1584, 1513, 1426, 1301, 1247, 1173, 1074, 1037, 905, 839, 766; HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{25}\text{INOSi}$ $[\text{M} + \text{H}]^+$: 426.0750, found: 426.0788.




2-Bromo-6-iodo-N-(4-methoxybenzyl)-4-methylaniline (S5): A solution of 2-bromo-6-iodo-4-methylaniline^{3,5} (3.12 g, 10.0 mmol), *p*-anisaldehyde (1.36 g, 10.0 mmol), and trifluoroacetic acid (.228 g, 2.00 mmol) in toluene (10 mL) was stirred in a round-bottom flask fitted with a Dean-Stark trap and a reflux condenser. The reaction mixture was refluxed for 12 h with azeotropic removal of water, cooled to room temperature, and solvent was removed by rotary evaporation. The crude residue was redissolved in EtOAc (30 mL) with stirring, trifluoroacetic acid (2.28 g, 20.0 mmol) was added, and the mixture was stirred for 30 min. Solid NaBH(OAc)₃ (4.24 g, 20.0 mmol) was added portionwise over 5 min, and the reaction mixture was stirred for 2 h at room temperature. The mixture was cooled to 0 °C, and quenched with 10% w/w aqueous NaOH solution (*very* slowly at first, until gas production stopped) until two distinct layers formed. The organic layer was separated and washed with brine (2 x 20 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (20:1 pentane:Et₂O) afforded the title compound (3.12 g, 72%) as a pink solid, mp 41-42 °C: ¹H NMR (300 MHz, CDCl₃) δ 7.59 (s, 1H), 7.39 (d, *J* = 8.7 Hz, 2H), 7.37 (s, 1H), 6.89 (d, *J* = 8.7 Hz, 2H), 4.22 (s, 2H), 3.82 (s, 3H), 2.25 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 158.9, 144.5, 139.5, 135.6, 134.1, 131.3, 129.6 (2C), 117.0, 113.8 (2C), 94.6, 55.2, 52.1, 19.7; FTIR (thin film, CHCl₃, cm⁻¹) 3332, 2993, 2958, 2927, 2831, 1610, 1584, 1510, 1455, 1244, 1173, 1034, 852, 826, 745, 714; LRMS (EI) *m/z* 433 (M⁺ (⁸¹Br), 7), 431 (M⁺ (⁷⁹Br), 7), 313 (5), 311 (5), 121 (100); HRMS (EI) calcd for C₁₅H₁₅⁷⁹BrINO: 430.9382, found: 430.9379.

Installation of Radical Acceptor Groups




Scheme S.2 Installation of Radical Acceptor Groups




(E)-tert-Butyl 3-(3,5-dimethyl-2-(methylamino)phenyl)acrylate (18a): In a round-bottom flask fitted with a reflux condenser were combined **17** (1.31 g, 5.00 mmol), K₂CO₃ (1.04 g, 7.50 mmol), *tert*-butyl acrylate (0.961 g, 7.50 mmol), and 10% Pd/C (0.186 g, 0.175 mmol) in DMF (10 mL). The stirred mixture was heated at 140 °C for 2 h, cooled to room temperature, and filtered through a pad of Celite, followed by rinsing the pad with Et₂O (100 mL). The combined filtrates were washed with water (3 x 100 mL) and brine (100 mL), dried over MgSO₄, filtered,

and concentrated by rotary evaporation. Column chromatography (5:1 hexanes:EtOAc) afforded the title compound (1.20 g, 92%) as a bright yellow solid, mp 76 °C: ¹H NMR (300 MHz, CDCl₃) δ 7.91 (d, *J* = 15.9 Hz, 1H), 7.17 (s, 1H), 6.98 (s, 1H), 6.29 (d, *J* = 15.9 Hz, 1H), 3.17 (br s, 1H), 2.81 (3H, s), 2.26 (s, 3H), 2.25 (s, 3H), 1.55 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.6, 146.2, 141.3, 132.9, 130.7, 129.1, 126.4, 126.0, 119.4, 79.9, 37.3, 28.1 (3C), 20.4, 17.6; FTIR (thin film, CHCl₃, cm⁻¹) 3390, 2976, 2931, 1705, 1628, 1480, 1367, 1332, 1278, 1151, 984, 757, 714; LRMS (EI) *m/z* 262 (M+H⁺, 1), 206 (65), 188 (100), 173 (66), 160 (96), 145 (41); HRMS (EI) calcd for C₁₆H₂₄NO₂ [M + H]⁺: 262.1807, found: 262.1794.




(E)-tert-Butyl 3-(2-(4-methoxybenzylamino)-3,5-dimethylphenyl)acrylate (18b): In a round-bottom flask fitted with a reflux condenser were combined **S1** (3.67 g, 10.0 mmol), K₂CO₃ (2.07 g, 15.0 mmol), *tert*-butyl acrylate (1.92 g, 15.0 mmol), and 10% Pd/C (0.372 g, 0.350 mmol) in DMF (20 mL). The stirred mixture was heated at 130 °C for 4 h, cooled to room temperature, diluted with Et₂O (200 mL), and filtered through a pad of Celite, followed by rinsing the pad with Et₂O (50 mL). The filtrate was washed with water (3 x 200 mL) and brine (200 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (10:1 hexanes:EtOAc) gave the title compound (3.02 g, 82%) as a bright yellow-green solid, mp 68-70 °C: ¹H NMR (300 MHz, CDCl₃) δ 8.00 (d, *J* = 15.9 Hz, 1H), 7.25 (d, *J* = 9.3 Hz, 2H), 7.21 (s, 1H), 6.97 (s, 1H), 6.86 (d, *J* = 8.7 Hz, 2H), 6.31 (d, *J* = 15.9 Hz, 1H), 4.04 (s, 2H), 3.81 (s, 2H), 3.27 (br s, 1H), 2.28 (s, 3H), 2.14 (s, 3H), 1.54 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.6,

158.8, 144.4, 141.3, 133.0, 132.2, 131.4, 129.8 (2C), 129.2, 127.2, 126.1, 119.8, 113.8 (2C), 80.0, 55.2, 54.7, 28.2 (3C), 20.6, 17.8; FTIR (thin film, CHCl₃, cm⁻¹) 3368, 2975, 2933, 2835, 1703, 1628, 1611, 1512, 1476, 1278, 1248, 1153, 1036, 983, 854, 823, 757; LRMS (EI) *m/z* 367 (M⁺, 14), 310 (6), 256 (9), 146 (11), 121 (100), 69 (55); HRMS (EI) calcd for C₂₃H₂₉NO₃: 367.2147, found: 367.2144.




(E)-tert-Butyl 3-(3-methoxy-2-(4-methoxybenzylamino)phenyl)acrylate (18c): In a round-bottom flask fitted with a reflux condenser were combined **S2** (3.32 g, 9.00 mmol), K₂CO₃ (1.87 g, 13.5 mmol), *tert*-butyl acrylate (1.73 g, 13.5 mmol), and 10% Pd/C (0.335 g, 0.315 mmol) in DMF (18 mL). The stirred mixture was heated at 130 °C for 4 h, cooled to room temperature, and filtered through a pad of Celite, followed by rinsing the pad with Et₂O (180 mL). Water (180 mL) was added to the filtrate, the organic layer was removed, and the aqueous layer was extracted with Et₂O (3 x 180 mL). The combined organic layers were washed with water (3 x 180 mL) and brine (180 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (3:1 hexanes:EtOAc) afforded the title compound (2.83 g, 85%) as a bright yellow-green solid, mp 67-68 °C: ¹H NMR (300 MHz, CDCl₃) δ 8.00 (d, *J* = 15.9 Hz, 1H), 7.27 (d, *J* = 9.0 Hz, 2H), 7.09 (dd, *J* = 7.8 Hz, 1.2 Hz, 1H), 6.88 (t, *J* = 8.1 Hz, 1H), 6.86 (d, *J* = 8.7 Hz, 2H), 6.81 (dd, *J* = 7.8 Hz, 1.2 Hz, 1H), 6.30 (d, *J* = 15.9 Hz, 1H), 4.29 (br s, 1H), 4.16 (s, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 1.53 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.3, 158.6, 150.9, 141.0, 138.5, 132.1, 128.9 (2C), 125.9, 120.8, 119.8, 119.5, 113.6 (2C), 111.0, 79.9, 55.6, 54.9, 54.2, 28.0 (3C); FTIR (thin film, CHCl₃, cm⁻¹) 3359, 2976, 2935, 2835,

1701, 1628, 1581, 1513, 1456, 1243, 1147, 1078, 1036, 983, 852, 824, 759; HRMS (ESI) calcd for C₂₂H₂₇NNaO₄ [M + Na]⁺: 392.1838, found: 392.1832.




(E)-tert-Butyl 3-(3,5-dimethyl-2-(4-methylphenylsulfonamido)phenyl)acrylate (18d): In a round-bottom flask fitted with a reflux condenser were combined **S3** (2.01 g, 5.00 mmol), K₂CO₃ (1.04 g, 7.50 mmol), *tert*-butyl acrylate (0.961 g, 7.50 mmol), and 10% Pd/C (0.186 g, 0.175 mmol) in DMF (10 mL). The stirred mixture was heated at 140 °C for 1 h, cooled to room temperature and filtered through a pad of Celite, followed by rinsing the pad with Et₂O (100 mL). Water (100 mL) was added to the filtrate, the organic layer was removed, and the aqueous layer was extracted with Et₂O (3 x 100 mL). The combined organic layers were washed with water (3 x 100 mL) and brine (100 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (3:1 hexanes:EtOAc) afforded the title compound (1.80 g, 90%) as a white solid, mp 150-152 °C: ¹H NMR (300 MHz, CDCl₃) δ 7.52 (d, *J* = 8.1 Hz, 2H), 7.39 (d, *J* = 15.9 Hz, 2H), 7.18 (s, 1H), 7.17 (d, *J* = 7.8 Hz, 2H), 7.09 (s, 1H), 6.49 (s, 1H), 5.99 (d, *J* = 15.9 Hz, 2H), 2.38 (s, 3H), 2.31 (s, 3H), 2.28 (s, 3H), 1.49 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.8, 143.5, 139.3, 139.0, 137.9, 136.3, 133.9, 133.6, 130.5, 129.6 (2C), 127.5 (2C), 125.2, 120.5, 80.3, 28.1 (3C), 21.6, 21.0, 18.8; FTIR (thin film, CHCl₃, cm⁻¹) 3256 (broad), 2978, 2928, 1691, 1633, 1331, 1258, 1160, 1092, 982, 899, 855, 814, 756; HRMS (ESI) calcd for C₂₂H₂₇NNaO₄S [M + Na]⁺: 424.1559, found: 424.1542.




(E)-tert-Butyl-3-(2-(4-methoxybenzylamino)-5-methyl-3-(trimethylsilyl)phenyl)acrylate


(18e): In a round-bottom flask fitted with a reflux condenser were combined **S4** (3.40 g, 8.00 mmol), K_2CO_3 (1.54 g, 12.0 mmol), *tert*-butyl acrylate (1.54 g, 12.0 mmol), and 10% Pd/C (0.298 g, 0.280 mmol) in DMF (16 mL). The stirred mixture was heated at 130 °C for 8 h, cooled to room temperature and filtered through a pad of Celite, followed by rinsing the pad with Et_2O (160 mL). Water (160 mL) was added to the filtrate, the organic layer was removed, and the aqueous layer was extracted with Et_2O (3 x 160 mL). The combined organic layers were washed with water (3 x 160 mL) and brine (160 mL), dried over $MgSO_4$, filtered, and concentrated by rotary evaporation. Column chromatography (10:1 pentane: Et_2O) afforded the title compound (2.62 g, 77%) as a bright yellow-green oil: 1H NMR (300 MHz, $CDCl_3$) δ 8.06 (d, $J = 16.2$ Hz, 1H), 7.38 (d, $J = 8.7$ Hz, 2H), 7.37 (s, 1H), 7.21 (d, $J = 1.5$ Hz, 1H), 6.31 (d, $J = 16.2$ Hz, 1H), 4.02 (br d, $J = 5.1$ Hz, 2H), 3.83 (s, 3H), 3.37 (br m, 1H), 2.32 (s, 3H), 1.53 (s, 9H), 0.30 (s, 9H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.5, 158.9, 151.1, 141.8, 137.5, 131.8, 131.6, 131.4, 129.9, 129.4 (2C), 127.5, 119.8, 113.9 (2C), 80.0, 56.0, 55.2, 28.2 (3C), 20.7, 0.2 (3C); FTIR (neat, cm^{-1}) 3391, 2955, 2836, 1705, 1629, 1514, 1455, 1320, 1250, 1152, 1037, 910, 883, 837, 734; LRMS (EI) m/z 425 (M^+ , 15), 369 (12), 309 (8), 216 (8), 121 (100); HRMS (EI) calcd for $C_{25}H_{35}NO_3Si$: 425.2386, found: 425.2389.




(E)-tert-Butyl 3-(3-bromo-2-(4-methoxybenzylamino)-5-methylphenyl)acrylate (18f): To a stirred solution of *o*-iodoaniline **S5** (1.73 g, 4.00 mmol) in DMF (20. mL) were added Bu₄NBr (1.29 g, 4.00 mmol), KOAc (1.18 g, 12.0 mmol), Pd(OAc)₂ (0.180 g, 0.80 mmol), and crushed activated 4Å molecular sieves (~2 g). Finally, *tert*-butyl acrylate (2.56 g, 20.0 mmol) was added, and the reaction mixture was stirred at room temperature for 2 days. The mixture was vacuum filtered through a Celite pad, and the pad was rinsed with Et₂O (200 mL). The filtrate was washed with saturated aqueous NaHCO₃ solution (200 mL), water (3 x 200 mL), and brine (200 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Gradient column chromatography (hexanes to 10:1 hexanes:EtOAc) furnished the title compound (1.40 g, 81%) as a bright yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.97 (d, *J* = 15.9 Hz, 1H), 7.34 (d, *J* = 1.5 Hz, 1H), 7.29 (d, *J* = 8.4 Hz, 2H), 7.25 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 6.31 (d, *J* = 15.9 Hz, 1H), 4.07 (d, *J* = 6.6 Hz, 2H), 3.97 (br t, *J* = 6.6 Hz, 1H), 3.82 (s, 3H), 2.28 (s, 3H), 1.54 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.1, 158.9, 143.5, 140.9, 134.0, 132.7, 131.5, 129.4 (2C), 128.4, 128.0, 120.8, 118.1, 113.8 (2C), 80.4, 55.2, 54.6, 28.2 (3C), 20.3; FTIR (neat, cm⁻¹) 3344, 2975, 2932, 2835, 1705, 1631, 1611, 1513, 1460, 1321, 1249, 1150, 1036, 980, 854, 828, 736; HRMS (ESI) calcd for C₂₂H₂₆⁷⁹BrNNaO₃ [M + Na]⁺: 454.0994, found: 454.0996.



(E)-2-(4-Bromostyryl)-N-(4-methoxybenzyl)-4,6-dimethylaniline (18g): In a round-bottom flask fitted with a reflux condenser were combined **S1** (1.84 g, 5.00 mmol), K_2CO_3 (1.04 g, 7.50 mmol), 4-bromostyrene (1.37 g, 7.50 mmol), and 10% Pd/C (0.186 g, 0.175 mmol) in DMF (10 mL). The stirred mixture was heated at 130 °C for 2 h, cooled to room temperature and filtered through a pad of Celite, followed by rinsing the pad with Et_2O (100 mL). Water (100 mL) was added to the filtrate, the organic layer was removed, and the aqueous layer was extracted with Et_2O (3 x 100 mL). The combined organic layers were washed with water (3 x 100 mL) and brine (100 mL), dried over $MgSO_4$, filtered, and concentrated by rotary evaporation. Gradient column chromatography (hexanes to 6:1 hexanes:EtOAc) gave the title compound (0.602 g, 29%) as a bright yellow solid, mp 63-65 °C: 1H NMR (300 MHz, $CDCl_3$) δ 7.48 (d, $J = 8.4$ Hz, 2H), 7.47 (d, $J = 15.9$ Hz, 1H), 7.35 (d, $J = 8.7$ Hz, 2H), 7.29 (s, 1H), 7.26 (d, $J = 8.7$ Hz, 2H), 6.95 (d, $J = 16.2$ Hz, 1H), 6.95 (s, 1H), 6.89 (d, $J = 8.4$ Hz, 2H), 4.13 (s, 2H), 3.82 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 158.8, 143.2, 136.9, 131.6 (2C), 131.5, 131.1, 129.9, 129.7, 129.0 (2C), 127.8 (2C), 127.3, 127.2, 125.3, 120.8, 113.9 (2C), 55.2, 54.1, 20.8, 17.9; FTIR (thin film, $CHCl_3$, cm^{-1}) 3363, 3001, 2912, 2834, 1610, 1511, 1487, 1246, 1175, 1072, 1035, 1007, 977, 908, 811, 732; HRMS (ESI) calcd for $C_{24}H_{25}NO^{79}Br$ $[M + H]^+$: 422.1120, found: 422.1133.




(E)-3-(2-(4-Methoxybenzylamino)-3,5-dimethylphenyl)acrylonitrile (18h): To a stirred solution of **S1** (1.84 g, 5.00 mmol) in DMF (25 mL) were added Bu₄NBr (1.61 g, 5.00 mmol), KOAc (1.47 g, 15.0 mmol), Pd(OAc)₂ (0.112 g, 0.50 mmol), and crushed activated 4Å molecular sieves (~2.5 g). Finally, acrylonitrile (1.33 g, 25.0 mmol) was added, and the reaction mixture was heated at 80 °C for 8 h. The mixture was cooled to room temperature, diluted with Et₂O (250 mL), and filtered through Celite, rinsing with Et₂O (25 mL). The filtrate was washed with saturated aqueous NaHCO₃ solution (250 mL), water (3 x 250 mL), and brine (250 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (4:1 hexanes:EtOAc) afforded the title compound (0.660 g, 45%) as a bright yellow-green oil, containing ~5% of an inseparable impurity by ¹H NMR: ¹H NMR (300 MHz, CDCl₃) δ 7.78 (d, *J* = 16.8 Hz, 1H), 7.17 (d, *J* = 8.7 Hz, 2H), 7.10 (s, 1H), 7.02 (s, 1H), 6.87 (d, *J* = 8.7 Hz, 2H), 5.86 (d, *J* = 16.8 Hz, 1H), 4.01 (br s, 2H), 3.82 (s, 3H), 3.27 (br s, 1H), 2.29 (s, 3H), 2.09 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 159.1, 148.8, 144.5, 134.1, 131.9, 131.8, 130.4, 129.1 (2C), 126.4, 125.6, 119.0, 114.1 (2C), 95.1, 55.3, 55.2, 20.6, 17.7; FTIR (neat, cm⁻¹) 3362, 3011, 2933, 2836, 2214, 1610, 1512, 1475, 1248, 1175, 1033, 982, 822, 755; HRMS (ESI) calcd for C₁₉H₂₁N₂O [M + H]⁺: 293.1654, found: 293.1678.



***N*-(4-Methoxybenzyl)-2,4-dimethyl-6-(2-methylprop-1-enyl)aniline (18i):** To a stirred solution of 2-methyl-1-propenylmagnesium bromide (7.17 g, 45.0 mmol) in THF (90. mL) at room temperature was added ZnCl₂ (6.13 g, 45.0 mmol) dropwise via syringe over 15 min. The mixture was stirred for 2 h, solid Pd(dppf)Cl₂•CH₂Cl₂ (0.184 g, 0.225 mmol) was added all at once, and the mixture was stirred an additional 5 min. **S1** (1.65 g, 4.50 mmol) in THF (20 mL) was added dropwise via syringe, the reaction mixture was stirred for 2.5 h at rt, cooled to 0 °C, and saturated aqueous NH₄Cl solution (200 mL) was added to quench the reaction. The mixture was extracted with Et₂O (3 x 200 mL), and the combined organic layers were washed with brine (200 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (10:1 hexanes:EtOAc) afforded the title compound (1.30 g, 98%) as a light yellow oil: ¹H NMR (300 MHz, CDCl₃) δ 7.24 (d, *J* = 8.7 Hz, 2H), 6.86 (d, *J* = 8.7 Hz, 2H), 6.85 (s, 1H), 6.79 (s, 1H), 6.15 (s, 1H), 4.03 (s, 2H), 3.81 (s, 3H), 3.33 (br s, 1H), 2.26 (s, 3H), 2.25 (s, 3H), 1.88 (d, *J* = 1.5 Hz, 3H), 1.73 (d, *J* = 1.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 158.5, 142.8, 135.3, 132.7, 130.3, 129.9, 129.8, 128.9 (2C), 128.7, 128.5, 122.9, 113.5 (2C), 54.8, 52.2, 25.8, 20.5, 19.2, 18.2; FTIR (neat, cm⁻¹) 3369, 2911, 1611, 1512, 1475, 1247, 1174, 1036, 861, 823, 737; LRMS (EI) *m/z* 295 (M⁺, 10), 252 (9), 174 (37), 121 (100); HRMS (EI) calcd for C₂₀H₂₅NO: 295.1936, found: 295.1925.


Preparation of α -Haloacetamide Precursors



| substrate | R ¹ | R ² | R ³ | R ⁴ | R ⁵ | α -Cl amide | % yield ^a | α -I amide | % yield ^a |
|------------|----------------|----------------|----------------|-----------------------------------|----------------|-----------------------|----------------------|----------------------|----------------------|
| 18a | Me | Me | Me | CO ₂ <i>t</i> -Bu | H | 19a | 90 | 15a | 93 |
| 18b | PMB | Me | Me | CO ₂ <i>t</i> -Bu | H | 19b | 97 | 15b | 92 |
| 18c | PMB | OMe | H | CO ₂ <i>t</i> -Bu | H | 19c | 85 | 15c | 98 |
| 18d | Ts | Me | Me | CO ₂ <i>t</i> -Bu | H | 19d | 89 | 15d | 78 |
| 18e | PMB | TMS | Me | CO ₂ <i>t</i> -Bu | H | 19e | 99 | 15e | 96 ^b |
| 18f | PMB | Br | Me | CO ₂ <i>t</i> -Bu | H | 19f | 90 | 15f | 91 |
| 18g | PMB | Me | Me | 4-BrC ₆ H ₄ | H | 19g | 89 | 15g | 86 |
| 18h | PMB | Me | Me | CN | H | 19h | 74 | 15h | 86 |
| 18i | PMB | Me | Me | Me | Me | 19i | 98 | 15i | 88 |


^a Yield of racemate after isolation by column chromatography. ^b The reaction mixture was refluxed for 40 h and reaction progress was monitored by GC.

General acylation procedure (compounds 19a-i): To a stirred solution of **18a-i** (1.0 equiv.) in CH₂Cl₂ (10 mL/mmol = *X* mL) at 0 °C was added Et₃N (2.0 equiv.) all at once, followed by chloroacetyl chloride (1.5 equiv.) dropwise via syringe. The mixture was stirred at 0 °C until completion, at which point saturated aqueous NH₄Cl solution (*X* mL) was added. The mixture was extracted with CH₂Cl₂ (3 x *X* mL), and the combined organic layers were washed with brine (*X* mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. The crude residue was subjected to column chromatography, using the appropriate eluent, to furnish the desired α -Cl amide **19a-i**.



***rac*-(*E*)-*tert*-Butyl 3-(2-(2-chloro-*N*-methylacetamido)-3,5-dimethylphenyl)acrylate (19a):**


Aniline **18a** (1.05 g, 4.00 mmol) was reacted according to the general procedure, and the reaction was complete after 2 h. After workup, column chromatography (2:1 hexanes:EtOAc) provided the title compound (1.21 g, 90%) as a white solid, mp 87 °C, as a mixture of amide rotamers in a 19:1 ratio: ¹H NMR (300 MHz, CDCl₃) Major rotamer δ 7.48 (d, *J* = 15.9 Hz, 1H), 7.35 (s, 1H), 7.16 (s, 1H), 6.36 (d, *J* = 15.9 Hz, 1H), 3.69 (d, *J* = 13.5 Hz, 1H), 3.64 (d, *J* = 13.5 Hz, 1H), 3.21 (s, 3H), 2.36 (s, 3H), 2.22 (s, 3H), 1.52 (s, 9H); minor rotamer δ 7.52 (d, *J* = 15.9 Hz, 1H), 7.35 (s, 1H), 7.12 (s, 1H), 6.35 (d, *J* = 15.9 Hz, 1H), 4.31 (d, *J* = 12.0 Hz, 1H), 4.23 (d, *J* = 12.0 Hz, 1H), 3.34 (s, 3H), 2.33 (s, 3H), 2.19 (s, 3H), 1.52 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.2, 165.2, 138.9, 137.22, 137.17, 136.0, 133.8, 132.3, 125.8, 123.4, 80.6, 41.3, 36.0, 27.9 (3C), 20.8, 17.2; FTIR (thin film, CHCl₃, cm⁻¹) 2978, 2931, 1712, 1475, 1368, 1330, 1256, 1154, 1110, 983, 855, 755; HRMS (ESI) calcd for C₁₈H₂₄ClNNaO₃ [*M* + Na]⁺: 360.1342, found: 360.1325.



***rac*-(*E*)-*tert*-Butyl-3-(2-(2-chloro-*N*-(4-methoxybenzyl)acetamido)-3,5-dimethylphenyl)**


acrylate (19b): Aniline **18b** (1.84 g, 7.00 mmol) was reacted according to the general procedure, and the reaction was complete after 3 h. After workup, column chromatography (3:1

hexanes:EtOAc) provided the title compound (3.01 g, 97%) as a yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 7.12 (d, $J = 15.9$ Hz, 2H), 7.09 (s, 1H), 7.07 (d, $J = 8.4$ Hz, 2H), 6.73 (d, $J = 8.7$ Hz, 2H), 6.14 (d, $J = 15.9$ Hz, 2H), 4.87 (d, $J = 13.8$ Hz, 1H), 4.58 (d, $J = 13.5$ Hz, 1H), 3.76 (s, 3H), 3.69 (d, $J = 13.8$ Hz, 1H), 3.64 (d, $J = 13.8$ Hz, 1H), 2.35 (s, 3H), 1.93 (s, 3H), 1.49 (s, 9 H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.6, 164.7, 159.0, 138.6, 137.4, 136.3, 135.1, 133.6, 132.8, 131.1 (2C), 127.1, 125.4, 122.2, 113.3 (2C), 80.0, 54.6, 52.0, 41.6, 27.6 (3C), 20.7, 17.2; FTIR (neat, cm^{-1}) 2977, 2933, 2837, 1708, 1667, 1513, 1469, 1327, 1248, 1152, 1035, 984, 851, 792, 733; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{30}\text{ClNNaO}_4$ [$\text{M} + \text{Na}$] $^+$: 466.1761, found: 466.1730.




***rac*-(*E*)-*t*-Butyl 3-(2-(2-chloro-*N*-(4-methoxybenzyl)acetamido)-3-methoxyphenyl) acrylate (19c):** Aniline **18c** (1.35 g, 3.65 mmol) was reacted according to the general procedure, and the reaction was complete after 1 h. After workup, column chromatography (2:1 hexanes:EtOAc) provided the title compound (1.39 g, 85%) as a yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 7.33 (t, $J = 8.1$ Hz, 1H), 7.24 (d, $J = 16.8$ Hz, 1H), 7.18 (d, $J = 7.8$ Hz, 1H), 7.01 (d, $J = 8.4$ Hz, 2H), 6.91 (d, $J = 8.4$ Hz, 1H), 6.69 (d, $J = 8.4$ Hz, 2H), 6.18 (d, $J = 15.9$ Hz, 1H), 4.85 (d, $J = 13.8$ Hz, 1H), 4.63 (d, $J = 13.8$ Hz, 1H), 3.76 (d, $J = 15.3$ Hz, 1H), 3.74 (s, 3H), 3.71 (d, $J = 14.7$ Hz, 1H), 3.64 (s, 3H), 1.50 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.7, 165.1, 159.0, 155.5, 137.3, 134.6, 131.2 (2C), 129.9, 127.8, 127.6, 123.3, 118.8, 113.3 (2C), 112.7, 80.7, 55.7, 55.0, 51.8, 42.5, 27.8 (3C); FTIR (neat, cm^{-1}) 2977, 2937, 2838, 2249, 1708, 1674, 1578, 1513, 1476, 1392,

1249, 1153, 1070, 1035, 984, 913, 849, 790, 733; HRMS (ESI) calcd for C₂₄H₂₈CINNaO₅ [M + Na]⁺: 468.1554, found: 468.1530.




***rac*-(*E*)-*tert*-Butyl 3-(2-(2-chloro-*N*-tosylacetamido)-3,5-dimethylphenyl)acrylate (19d):**

Aniline **18d** (1.20 g, 3.00 mmol) was reacted according to the general procedure, and the reaction was complete after 1 h. After workup, column chromatography (4:1 hexanes:EtOAc) provided the title compound (1.27 g, 89%) as a white solid, mp 170 °C (decomp.): ¹H NMR (300 MHz, CDCl₃) δ 8.02 (d, *J* = 8.4 Hz, 2H), 7.43 (s, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.27 (d, *J* = 15.9 Hz, 1H), 7.24 (s, 1H), 6.38 (d, *J* = 15.9 Hz, 1H), 3.66 (s, 2H), 2.46 (s, 3H), 2.404 (s, 3H), 2.396 (s, 3H), 1.47 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.0, 164.7, 145.5, 140.8, 139.4, 137.2, 134.3, 134.1 (2C, accidental isochrony), 130.6, 130.2 (2C), 129.3 (2C), 125.9, 123.9, 80.6, 43.2, 27.8 (3C), 21.6, 21.1, 18.7; FTIR (thin film, CHCl₃, cm⁻¹) 2979, 1709, 1367, 1307, 1264, 1170, 1085, 983, 886, 814, 757; HRMS (ESI) calcd for C₂₄H₂₈CINNaO₅S: [M + Na]⁺: 500.1274, found: 500.1273.




***rac*-(*E*)-*t*-Butyl 3-(2-(2-chloro-*N*-(4-methoxybenzyl)acetamido)-5-methyl-3-(trimethylsilyl)phenyl)acrylate (19e):** Aniline **18e** was reacted according to the general procedure, and the reaction was complete after 7 h. After workup, column chromatography (5:1 hexanes:EtOAc) provided the title compound (2.50 g, 99%) as a white solid, mp 69-71 °C: ^1H NMR (300 MHz, CDCl_3) δ 7.47 (d, $J = 1.8$ Hz, 1H), 7.34 (s, 1H), 7.03 (d, $J = 8.4$ Hz, 2H), 6.71 (d, $J = 8.4$ Hz, 2H), 6.68 (d, $J = 15.9$ Hz, 1H), 5.92 (d, $J = 15.9$ Hz, 1H), 5.76 (d, $J = 13.5$ Hz, 1H), 3.76 (d, $J = 11.7$ Hz, 3.74 (s, 3H), 3.73 (d, $J = 14.1$ Hz, 1H), 3.67 (d, $J = 13.8$ Hz, 1H), 2.39 (s, 3H), 1.44 (s, 9H), 0.35 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.1, 164.5, 159.1, 140.8, 139.3, 139.2, 138.1, 137.5, 133.6, 131.3 (2C), 128.5, 126.7, 121.9, 113.5 (2C), 79.9, 54.7, 54.1, 42.2, 27.7 (3C), 20.9, 0.1 (t, $J_{\text{Si-C}} = 26.3$ Hz, 3C); FTIR (thin film, CHCl_3 , cm^{-1}) 2977, 1707, 1670, 1512, 1437, 1320, 1252, 1155, 982, 874, 839, 757; HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{36}\text{ClNNaO}_4\text{Si}$ [$\text{M} + \text{Na}$] $^+$: 524.2000, found: 524.1974.



***rac*-(*E*)-*tert*-Butyl 3-(3-bromo-2-(2-chloro-*N*-(4-methoxybenzyl)acetamido)-5-methylphenyl)acrylate (19f):** Aniline **18f** (2.34 g, 5.50 mmol) was reacted according to the general procedure, and the reaction was complete after 2 h. After workup, column chromatography (3:1


hexanes:EtOAc) provided the title compound (2.51 g, 90%) as a white solid, mp 117 °C: ^1H NMR (300 MHz, CDCl_3) δ 7.53 (d, $J = 1.2$ Hz, 1H), 7.31 (d, $J = 1.2$ Hz, 1H), 7.03 (d, $J = 8.7$ Hz, 2H), 6.97 (d, $J = 15.9$ Hz, 1H), 6.71 (d, $J = 8.7$ Hz, 2H), 6.01 (d, $J = 15.9$ Hz, 1H), 5.38 (d, $J = 13.8$ Hz, 1H), 4.21 (d, $J = 14.1$ Hz, 1H), 3.78 (d, $J = 13.8$ Hz, 1H), 3.75 (s, 3H), 3.66 (d, $J = 14.1$ Hz, 1H), 2.38 (s, 3H), 1.48 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 165.6, 164.5, 159.3, 140.8, 136.9, 135.9, 135.4, 134.9, 131.5 (2C), 127.0, 126.7, 124.6, 123.3, 113.6 (2C), 80.6, 54.9, 51.9, 42.3, 27.9 (3C), 20.8; FTIR (thin film, CHCl_3 , cm^{-1}) 3007, 2978, 2934, 1709, 1513, 1459, 1323, 1249, 1152, 1036, 983, 851, 826, 756; HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{27}^{79}\text{BrCINNaO}_4$ [$\text{M} + \text{Na}$] $^+$: 530.0710, found: 530.0761.



***rac*-(*E*)-*N*-(2-(4-Bromostyryl)-4,6-dimethylphenyl)-2-chloro-*N*-(4-methoxybenzyl)acetamide**


(19g): Aniline **18g** (0.472 g, 1.12 mmol) was reacted according to the general procedure, and the reaction was complete after 2 h. After workup, column chromatography (4:1 hexanes:EtOAc) provided the title compound (0.498 g, 89%) as a yellow solid, mp 130-131 °C: ^1H NMR (300 MHz, CDCl_3) δ 7.38 (d, $J = 8.4$ Hz, 2H), 7.33 (s, 1H), 7.20 (d, $J = 8.7$ Hz, 2H), 7.06 (s, 1H), 6.99 (d, $J = 8.4$ Hz, 2H), 6.81 (d, $J = 16.2$ Hz, 1H), 6.71 (d, $J = 8.7$ Hz, 2H), 6.41 (d, $J = 16.2$ Hz, 2H), 5.24 (d, $J = 13.5$ Hz, 1H), 4.24 (d, $J = 13.5$ Hz, 1H), 3.68 (s, 2H), 3.65 (s, 3H), 2.38 (s, 3H), 2.08 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.5, 159.3, 138.8, 136.1, 135.6, 135.4, 134.9, 132.0, 131.54 (2C), 131.50 (2C), 129.8, 128.2, 128.1 (2C), 124.5, 124.1, 121.7, 113.7 (2C), 55.0, 52.6, 42.3, 21.2, 17.8; FTIR (thin film, CHCl_3 , cm^{-1}) 3001, 2932, 2835, 1667, 1512, 1488, 1394, 1325,

1303, 1247, 1176, 1035, 1008, 965, 910, 849, 810, 732; HRMS (ESI) calcd for $C_{26}H_{25}^{79}BrClINNaO_2 [M + Na]^+$: 520.0655, found: 520.0690.



***rac*-(*E*)-2-Chloro-*N*-(2-(2-cyanovinyl)-4,6-dimethylphenyl)-*N*-(4-methoxybenzyl)acetamide**


(19h): Aniline **18h** (0.731 g, 2.50 mmol) was reacted according to the general procedure, and the reaction was complete after 5 h. After workup, column chromatography (2:1 hexanes:EtOAc) provided the title compound (0.687 g, 74%) as a white solid, mp 159-160 °C: 1H NMR (300 MHz, $CDCl_3$) δ 7.22 (s, 1H), 7.16 (s, 1H), 7.06 (d, $J = 8.4$ Hz, 2H), 6.80 (d, $J = 8.7$ Hz, 2H), 6.70 (d, $J = 16.5$ Hz, 1H), 5.56 (d, $J = 16.8$ Hz, 1H), 5.31 (d, $J = 13.5$ Hz, 1H), 4.13 (d, $J = 13.5$ Hz, 1H), 3.83 (s, 3H), 3.64 (d, $J = 13.2$ Hz, 1H), 3.59 (d, $J = 13.5$ Hz, 1H), 2.37 (s, 3H), 2.10 (s, 3H); ^{13}C NMR (75 MHz, $CDCl_3$) δ 166.0, 159.7, 144.8, 139.4, 136.9, 135.2, 135.1, 132.2, 131.4 (2C), 127.0, 124.6, 117.4, 114.0 (2C), 97.8, 55.2, 52.2, 41.6, 21.0, 17.6; FTIR (thin film, $CHCl_3$, cm^{-1}) 3012, 2936, 2837, 2218, 1669, 1612, 1513, 1467, 1392, 1249, 1176, 1111, 1033, 966, 849, 761; LRMS (EI) m/z 368 (M^+ , 8), 304 (12), 291 (15), 183 (10), 169 (15), 155 (18), 121 (100), 91 (37), 84 (50); HRMS (EI) calcd for $C_{21}H_{21}ClN_2O_2$: 368.1292, found: 368.1295.




***rac*-2-Chloro-*N*-(2,4-dimethyl-6-(2-methylprop-1-enyl)phenyl)-*N*-(4-methoxybenzyl)**

acetamide (19i): Aniline **18i** (0.886 g, 3.00 mmol) was reacted according to the general procedure, and the reaction was complete after 90 min. After workup, column chromatography (4:1 hexanes:EtOAc) provided the title compound (1.09 g, 98%) as a yellow oil: ^1H NMR (300 MHz, CDCl_3) δ 7.13 (d, $J = 8.4$ Hz, 2H), 6.90 (s, 2H), 6.75 (d, $J = 8.4$ Hz, 2H), 5.60 (s, 1H), 4.74 (d, $J = 13.8$ Hz, 1H), 4.62 (d, $J = 13.8$ Hz, 1H), 3.78 (s, 3H), 3.67 (d, 2H), 2.32 (s, 3H), 1.84 (s, 3H), 1.72 (s, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.1, 158.9, 137.7, 137.4, 136.5, 135.5, 134.7, 131.1 (2C), 130.1, 129.5, 128.4, 121.2, 113.3 (2C), 54.9, 51.7, 41.9, 26.2, 20.8, 19.0, 17.4; FTIR (neat, cm^{-1}) 2933, 2836, 1667, 1512, 1441, 1247, 1176, 1110, 1035, 915, 849, 822, 791, 733; HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{26}\text{ClNNaO}_2$ [$\text{M} + \text{Na}$] $^+$: 394.1550, found: 394.1529.

General procedure for Finkelstein reactions (Compounds 15a-i): To a solution of α -Cl amide **19a-i** (1.0 equiv.) in acetone (10 mL/mmol = X mL) was added NaI (10.0 equiv.) all at once, and the reaction mixture was stirred at room temperature overnight (16-20 h). The mixture was diluted with Et_2O (10 X mL) and washed with 10% aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (3 x X mL), dried over MgSO_4 , filtered, and concentrated by rotary evaporation. The crude residue was subjected to column chromatography, using the appropriate eluent, to furnish the desired product.




(E)-*t*-Butyl 3-(2-(2-iodo-*N*-methylacetamido)-3,5-dimethylphenyl)acrylate (15a): Chloride *rac*-**19a** (1.01 g, 3.00 mmol) was reacted according to the general procedure. Column chromatography (2:1 hexanes:EtOAc) furnished *rac*-**15a** (1.20 g, 93%) as a yellow oil in a 14:1 ratio of amide rotamers. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 80:20 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_D^{23} -153$, 85/15 er (*c* 6.7 mg/mL, CHCl₃), second eluting enantiomer $[\alpha]_D^{23} +131$, 98.5/1.5 er (*c* 4.7 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) major rotamer δ 7.55 (d, *J* = 15.9 Hz, 1H), 7.36 (s, 1H), 7.15 (s, 1H), 6.35 (d, *J* = 15.9 Hz, 1H), 3.48 (d, *J* = 10.2 Hz, 1H), 3.44 (d, *J* = 10.2 Hz, 1H), 3.17 (s, 3H), 2.36 (s, 3H), 2.26 (s, 3H), 1.52 (s, 9H); minor rotamer δ 7.55 (d, *J* = 15.9 Hz, 1H), 7.31 (s, 1H), 7.09 (s, 1H), 6.34 (d, *J* = 15.9 Hz, 1H), 3.96 (d, *J* = 9.6 Hz, 1H), 3.88 (d, *J* = 9.6 Hz, 1H), 3.28 (s, 3H), 2.32 (s, 3H), 2.26 (s, 3H), 1.52 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) major rotamer only δ 167.7, 165.1, 138.6, 137.6, 135.6, 133.7, 131.9, 125.7, 123.1, 80.3, 36.2, 27.9, 27.9 (3C), 20.8, 17.5, -3.7; FTIR (neat, cm⁻¹) 2977, 2930, 2246, 1708, 1662, 1474, 1427, 1367, 1329, 1300, 1253, 1153, 1096, 983, 916, 855, 732; HRMS (ESI) calcd for C₁₈H₂₄INNaO₃ [M + Na]⁺: 452.0699, found: 452.0661.



(E)-tert-Butyl 3-(2-(2-iodo-N-(4-methoxybenzyl)acetamido)-3,5-dimethylphenyl)acrylate


(15b): Chloride *rac*-**19b** (2.00 g, 4.50 mmol) was reacted according to the general procedure. Column chromatography (2:1 hexanes:EtOAc) furnished *rac*-**15b** (2.22 g, 92%) as a yellow oil. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 70:30 hexanes:iPrOH), first eluting enantiomer $[\alpha]_D^{23} -16$, 100/0 er (*c* 16.7 mg/mL, CHCl₃), second eluting enantiomer $[\alpha]_D^{23} +15$, 100/0 er (*c* 9.5 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.27 (s, 1H), 7.19 (d, *J* = 15.9 Hz, 1H), 7.10 (s, 1H), 7.05 (d, *J* = 8.7 Hz, 2H), 6.72 (d, *J* = 8.7 Hz, 2H), 6.13 (d, *J* = 15.9 Hz, 1H), 3.76 (s, 3H), 3.47 (s, 2H), 2.35 (s, 3H), 1.98 (s, 3H), 1.49 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 167.5, 165.2, 159.2, 138.6, 138.3, 136.5, 136.4, 133.8, 132.9, 131.4 (2C), 127.5, 125.7, 122.4, 113.6 (2C), 80.4, 55.0, 52.4, 28.0 (3C), 21.0, 18.0, -2.5; FTIR (thin film, CHCl₃, cm⁻¹) 2977, 2933, 2836, 1707, 1655, 1512, 1469, 1368, 1326, 1303, 1249, 1158, 1036, 984, 912, 852, 732; HRMS (ESI) calcd for C₂₅H₃₀INNaO₄ [M + Na]⁺: 558.1117, found: 558.1071.



(E)-tert-Butyl 3-(2-(2-iodo-N-(4-methoxybenzyl)acetamido)-3-methoxyphenyl)acrylate (15c):


Chloride *rac*-**19c** (0.981 g, 2.20 mmol) was reacted according to the general procedure. Column chromatography (2:1 hexanes:EtOAc) furnished *rac*-**15c** (1.16 g, 98%) as a yellow oil. The

racemate was submitted to preparative chiral HPLC separation (Chiralcel OD, 90:10 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_D^{23} -27$, 99/1 er (*c* 9.5 mg/mL, CHCl₃), second eluting enantiomer $[\alpha]_D^{23} +28$, 99/1 er (*c* 13.6 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.32 (t, *J* = 7.8 Hz, 1H), 7.30 (d, *J* = 16.2 Hz, 1H), 7.18 (d, *J* = 7.8 Hz, 1H), 7.00 (d, *J* = 8.7 Hz, 2H), 6.90 (d, *J* = 8.1 Hz, 1H), 6.69 (d, *J* = 8.7 Hz, 2H), 6.16 (d, *J* = 16.2 Hz, 1H), 4.87 (d, *J* = 13.8 Hz, 1H), 4.56 (d, *J* = 13.8 Hz, 1H), 3.74 (s, 3H), 3.67 (s, 3H), 3.50 (s, 2H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 168.0, 165.0, 158.8, 155.2, 137.6, 134.1, 131.0 (2C), 129.6, 128.5, 127.7, 122.7, 118.5, 113.1 (2C), 112.7, 80.3, 55.5, 54.9, 51.6, 27.9, -2.1; FTIR (neat, cm⁻¹) 2976, 2935, 2837, 1708, 1659, 1577, 1513, 1368, 1248, 1153, 1070, 1035, 983, 849, 913, 849, 800, 732; HRMS (ESI) calcd for C₂₄H₂₈INNaO₅ [M + Na]⁺: 560.0910, found: 560.0901.




(*E*)-tert-Butyl 3-(2-(2-iodo-*N*-tosylacetamido)-3,5-dimethylphenyl)acrylate (15d**):** Chloride *rac*-**19d** (0.717 g, 1.50 mmol) was reacted according to the general procedure. Column chromatography (2:1 hexanes:EtOAc) furnished *rac*-**15d** (0.662 g, 78%) as a white solid, mp 205 °C (decomp.): ¹H NMR (300 MHz, CDCl₃) δ 8.00 (d, *J* = 8.1 Hz, 2H), 7.43 (s, 1H), 7.33 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 15.6 Hz, 1H), 7.25 (s, 1H), 6.37 (d, *J* = 15.9 Hz, 1H), 3.48 (s, 2H), 2.46 (2 overlapping s, 2 x 3H), 2.41 (s, 3H), 1.47 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.7, 165.0, 145.5, 140.6, 139.6, 137.9, 134.5, 134.3, 134.1, 132.0, 130.4 (2C), 129.4 (2C), 125.9, 123.7, 80.6, 28.0 (3C), 21.8, 21.2, 19.3, -2.2; FTIR (thin film, CHCl₃, cm⁻¹) 2978, 1705, 1365, 1275,

1171, 1083, 982, 885, 815, 758; HRMS (ESI) calcd for C₂₄H₂₈INNaO₅S [M + Na]⁺: 592.0631, found: 592.0616.




(*E*)-*t*-Butyl 3-(2-(2-iodo-*N*-(4-methoxybenzyl)acetamido)-5-methyl-3-(trimethylsilyl)phenyl)acrylate (15e**):** In a round bottom flask equipped with a reflux condenser, chloride *rac*-**19e** (1.51 g, 3.00 mmol) was mixed with NaI (4.50 g, 30.0 mmol) in acetone (30 mL). The stirred mixture was refluxed for 40 h until complete conversion had been achieved (monitored using GC). The mixture was cooled to room temperature, and was worked up according to the general procedure. Column chromatography (5:1 hexanes:EtOAc) furnished *rac*-**15e** (2.88 g, 96%) as a glassy yellow solid, mp 51-53 °C. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 70:30 hexanes:*i*-PrOH), first eluting enantiomer [α]_D²³ +86, 100/0 er (*c* 8.8 mg/mL, CHCl₃), second eluting enantiomer [α]_D²³ -87, 100/0 er (*c* 12.2 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.47 (d, *J* = 1.8 Hz, 1H), 7.35 (d, *J* = 1.8 Hz, 1H), 7.02 (d, *J* = 8.7 Hz, 2H), 6.78 (d, *J* = 15.9 Hz, 1H), 6.70 (d, *J* = 8.7 Hz, 2H), 5.92 (d, *J* = 15.9 Hz, 1H), 5.70 (d, *J* = 13.5 Hz, 1H), 3.77 (d, *J* = 13.5 Hz, 1H), 3.74 (s, 3H), 3.55 (d, *J* = 11.1 Hz, 1H), 3.51 (d, *J* = 11.4 Hz, 1H), 2.39 (s, 3H), 1.45 (s, 9H), 0.36 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 165.5, 164.3, 158.9, 141.7, 138.9, 137.8, 137.6, 133.2, 131.1 (2C), 128.2, 126.5, 121.3, 113.3 (2C), 79.5, 54.5, 54.2, 27.6 (3C), 20.8, 0.18 (3C), -0.6; FTIR (thin film, CHCl₃, cm⁻¹) 2976, 2836, 1706, 1659, 1512, 1437, 1367, 1320, 1250, 1161, 1109, 1036, 1007, 983, 874, 838, 757; HRMS (ESI) calcd for C₂₇H₃₆INNaO₄Si [M + Na]⁺: 616.1356, found: 616.1395.




(*E*)-*t*-Butyl 3-(3-bromo-2-(2-iodo-*N*-(4-methoxybenzyl)acetamido)-5-methylphenyl) acrylate

(15f): Chloride *rac*-**19f** (2.20 g, 4.32 mmol) was reacted according to the general procedure. Column chromatography (3:1 hexanes:EtOAc) furnished *rac*-**15f** (2.35 g, 91%) as a sticky yellow semi-solid. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 70:30 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_D^{23} +21$, 99/1 er (*c* 14.4 mg/mL, CHCl₃), second eluting enantiomer $[\alpha]_D^{23} -19$, 100/0 er (*c* 10.9 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.50 (d, *J* = 1.2 Hz, 1H), 7.33 (s, 1H), 7.11 (d, *J* = 15.9 Hz, 1H), 7.02 (d, *J* = 8.7 Hz, 2H), 6.70 (d, *J* = 8.7 Hz, 2H), 6.01 (d, *J* = 15.9 Hz, 1H), 5.27 (d, *J* = 14.1 Hz, 1H), 4.26 (d, *J* = 13.8 Hz, 1H), 3.74 (s, 3H), 3.58 (d, *J* = 10.8 Hz, 1H), 3.44 (d, *J* = 10.5 Hz, 1H), 2.38 (s, 3H), 1.48 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.9, 164.3, 159.0, 140.4, 137.3, 135.8, 135.3, 135.2, 131.2 (2C), 126.8, 126.6, 124.3, 122.7, 113.4 (2C), 80.2, 54.7, 51.8, 27.7 (3C), 20.7, -2.5; FTIR (thin film, CHCl₃, cm⁻¹) 2977, 2932, 2836, 1708, 1665, 1513, 1459, 1368, 1321, 1248, 1154, 1035, 982, 851, 822, 756; HRMS (ESI) calcd for C₂₄H₂₇⁷⁹BrINNaO₄ [M + Na]⁺: 622.0066, found: 622.0031.



(E)-N-(2-(4-Bromostyryl)-4,6-dimethylphenyl)-2-iodo-N-(4-methoxybenzyl)acetamide


(15g): Chloride *rac*-**19g** (0.399 g, 0.800 mmol) was reacted according to the general procedure. Column chromatography (4:1 hexanes:EtOAc) furnished *rac*-**15g** (0.408 g, 86%) as a yellow-orange solid, mp 97-98 °C: ^1H NMR (300 MHz, CDCl_3) δ 7.39 (d, $J = 8.4$ Hz, 2H), 7.34 (s, 1H), 7.17 (d, $J = 8.7$ Hz, 2H), 7.05 (s, 1H), 7.04 (d, $J = 8.4$ Hz, 2H), 6.80 (d, $J = 16.2$ Hz, 1H), 6.70 (d, $J = 8.4$ Hz, 2H), 6.51 (d, $J = 16.2$ Hz, 1H), 5.14 (d, $J = 13.5$ Hz, 1H), 4.28 (d, $J = 13.5$ Hz, 1H), 3.64 (s, 3H), 3.50 (d, $J = 10.2$ Hz, 1H), 3.46 (d, $J = 10.2$ Hz, 1H), 2.38 (s, 3H), 2.10 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 168.1, 159.2, 138.6, 136.0, 135.9, 135.7, 135.0, 132.0, 131.5 (4C = two overlapping 2C), 129.4, 128.2, 128.1 (2C), 124.7, 124.5, 121.6, 113.7 (2C), 55.0, 52.6, 21.2, 18.1, -2.1; FTIR (thin film, CHCl_3 , cm^{-1}) 3002, 2933, 2835, 1651, 1512, 1487, 1386, 1322, 1302, 1249, 1176, 1107, 1073, 1035, 1008, 909, 849, 810, 732; HRMS (ESI) calcd for $\text{C}_{26}\text{H}_{25}^{79}\text{BrINNaO}_2$ [$\text{M} + \text{Na}$] $^+$: 612.0011, found: 612.0002.



(E)-N-(2-(2-cyanovinyl)-4,6-dimethylphenyl)-2-iodo-N-(4-methoxybenzyl)acetamide (15h):

To a solution of chloride *rac*-**19h** (0.619 g, 1.60 mmol) in acetone (65 mL) was added NaI (2.40 g, 16.0 mmol) all at once and the reaction mixture was stirred at room temperature overnight.


After 16 h, 10% aqueous Na₂S₂O₃ (65 mL) was added and the mixture was extracted with EtOAc (3 x 160 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (2:1 hexanes:EtOAc) furnished *rac*-**15h** (0.633 g, 86%) as a white solid, mp 144-145 °C. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 80:20 hexanes:EtOAc), first eluting enantiomer [α]_D²³ -0.4, 99/1 er (*c* 11.2 mg/mL, CHCl₃), second eluting enantiomer [α]_D²³ +0.5, 99.5/0.5 er (*c* 43.9 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.27 (s, 1H), 7.21 (s, 1H), 7.04 (d, *J* = 8.7 Hz, 2H), 6.81 (d, *J* = 16.8 Hz, 1H), 6.80 (d, *J* = 7.8 Hz, 2H), 5.56 (d, *J* = 16.5 Hz, 1H), 5.22 (d, *J* = 13.5 Hz, 1H), 4.16 (d, *J* = 13.8 Hz, 1H), 3.82 (s, 3H), 3.44 (d, *J* = 10.2 Hz, 1H), 3.39 (d, *J* = 10.2 Hz, 1H), 2.37 (s, 3H), 2.11 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 167.5, 159.6, 145.3, 139.1, 136.7, 136.1, 135.2, 131.8, 131.3 (2C), 127.1, 124.6, 117.5, 113.9 (2C), 97.4, 55.2, 52.2, 21.0, 17.9, -3.2; FTIR (thin film, CHCl₃, cm⁻¹) 3004, 2934, 2217, 1655, 1512, 1385, 1304, 1250, 1176, 1107, 1033, 1007, 965, 849, 822, 755; HRMS (ESI) calcd for C₂₁H₂₁IN₂NaO₂ [M + Na]⁺: 483.0545, found: 483.0533.



***N*-(2,4-Dimethyl-6-(2-methylprop-1-enyl)phenyl)-2-iodo-*N*-(4-methoxybenzyl)acetamide**


(15i): Chloride *rac*-**19i** (0.744 g, 2.00 mmol) was reacted according to the general procedure. Column chromatography (4:1 hexanes:EtOAc) furnished *rac*-**15i** (0.816 g, 88%) as a white solid, mp 73-74 °C. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 80:20 hexanes:*i*-PrOH), first eluting enantiomer [α]_D²³ -4.4, 99/1 er (*c* 2.8 mg/mL, CHCl₃),

second eluting enantiomer $[\alpha]_D^{23} +4.2$, 100/0 er (*c* 5.2 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.11 (d, *J* = 8.7 Hz, 2H), 6.90 (br s, 2H), 6.74 (d, *J* = 8.7 Hz, 2H), 5.69 (s, 1H), 4.70 (d, *J* = 13.5 Hz, 1H), 4.61 (d, *J* = 13.8 Hz, 1H), 3.77 (s, 3H), 3.47 (s, 2H), 2.32 (s, 3H), 1.89 (s, 3H), 1.72 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 167.5, 158.9, 137.4, 137.2, 136.3, 135.8, 135.3, 131.1 (2C), 130.1, 129.4, 128.4, 121.6, 113.3 (2C), 54.9, 51.7, 26.3, 20.9, 19.1, 17.8, -1.6; FTIR (thin film, CHCl₃, cm⁻¹) 2931, 2857, 2835, 1655, 1612, 1512, 1440, 1385, 1303, 1247, 1176, 1107, 1035, 849, 835, 822, 756; HRMS (ESI) calcd for C₂₂H₂₆INNaO₂ [M + Na]⁺: 486.0906, found: 486.0867.




(*E*)-*t*-Butyl 3-(2-(2-bromo-*N*-(4-methoxybenzyl)propanamido)-3-methoxyphenyl) acrylate (25a and 25b): To a stirred solution of **18c** (1.11 g, 3.00 mmol) and Et₃N (0.455 g, 4.50 mmol) in THF (6.0 mL) at 0 °C was added 2-bromopropionyl bromide (0.971 g, 4.50 mmol) dropwise via syringe. The mixture was stirred at 0 °C for 30 min, and saturated aqueous NH₄Cl (15 mL) was added. The mixture was extracted with Et₂O (3 x 30 mL), and the combined organic layers were washed with brine (30 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (3:1 hexanes:EtOAc) provided two diastereomers. The first eluting diastereomer, *rac*-**25a**, was isolated (0.497 g, 33%) as a clear, pale yellow oil. This racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 75:25 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_D^{23} +47$, 98/2 er (*c* 13.4 mg/mL, CHCl₃), second eluting enantiomer $[\alpha]_D^{23} -48$, 99/1 er (*c* 15.1 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.34 (t, *J* = 8.1 Hz, 1H), 7.12 (d, *J* = 7.8 Hz, 1H), 7.03 (d, *J* = 8.7 Hz, 2H), 7.00 (d, *J* = 8.7 Hz,

2H), 6.90 (d, $J = 15.9$ Hz, 1H), 6.69 (d, $J = 8.7$ Hz, 1H), 5.43 (d, $J = 15.9$ Hz, 1H), 4.15 (d, $J = 13.8$ Hz, 1H), 4.01 (q, $J = 6.6$ Hz, 1H), 3.84 (s, 3H), 3.73 (s, 3H), 1.69 (d, $J = 6.6$ Hz, 3H), 1.46 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 169.7, 165.0, 159.1, 155.7, 137.3, 134.7, 131.3 (2C), 129.7, 128.0, 127.9, 123.2, 118.0, 113.5 (2C), 113.1, 80.5, 55.7, 55.0, 51.3, 39.1, 28.0 (3C), 22.1; FTIR (neat, cm^{-1}) 2975, 2936, 2838, 2249, 1708, 1666, 1612, 1578, 1513, 1477, 1394, 1272, 1248, 1175, 1154, 1072, 1036, 984, 912, 849, 800, 733; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{30}\text{BrNNaO}_5$ $[\text{M} + \text{Na}]^+$: 526.1205, found: 526.1214. The second eluting diastereomer, *rac*-**25b**, was isolated (0.983 g, 65%) as a clear, colorless oil. This racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 70:30 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_{\text{D}}^{23} +66$, 100/0 er (*c* 9.9 mg/mL, CHCl_3), second eluting enantiomer $[\alpha]_{\text{D}}^{23} -67$, 100/0 er (*c* 6.3 mg/mL, CHCl_3): ^1H NMR (300 MHz, CDCl_3) δ 7.55 (d, $J = 15.9$ Hz, 1H), 7.31 (t, $J = 8.1$ Hz, 1H), 7.23 (d, $J = 8.1$ Hz, 1H), 6.98 (d, $J = 8.7$ Hz, 2H), 6.85 (d, $J = 7.8$ Hz, 1H), 6.68 (d, $J = 8.4$ Hz, 2H), 6.20 (d, $J = 15.9$ Hz, 1H), 4.82 (d, $J = 13.8$ Hz, 1H), 4.56 (d, $J = 13.8$ Hz, 1H), 4.11 (q, $J = 6.6$ Hz, 1H), 3.74 (s, 3H), 3.53 (s, 3H), 1.74 (d, $J = 6.6$ Hz, 3H), 1.51 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.8, 165.2, 158.9, 155.3, 138.2, 134.4, 131.0 (2C), 129.5, 128.3, 127.9, 122.6, 119.0, 113.1 (2C), 112.3, 80.3, 55.5, 54.9, 51.7, 39.6, 27.9 (3C), 21.7; FTIR (neat, cm^{-1}) 2976, 2934, 2839, 1708, 1670, 1577, 1513, 1475, 1394, 1368, 1271, 1248, 1152, 1068, 984, 849, 801, 732; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{30}\text{BrNNaO}_5$ $[\text{M} + \text{Na}]^+$: 526.1205, found: 526.1206.



***rac*-2-Bromopent-4-enoic acid (S6):** To a stirred solution of NaBr (6.47 g, 62.9 mmol) in aqueous HBr (0.75 M, 60 mL) at -15 °C was added, in one portion, NaNO_2 (1.52 g, 22.1 mmol). After stirring at this temperature for 15 min, (\pm)-2-amino-4-pentenoic acid (1.96 g, 17.0 mmol)

was added in one portion. The reaction mixture was stirred at $-15\text{ }^{\circ}\text{C}$ for 1 h, $0\text{ }^{\circ}\text{C}$ for 1 h, and at room temperature for 2 h, and was then extracted with EtOAc (3 x 125 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated by rotary evaporation. Column chromatography (50:50:1 hexanes:EtOAc:AcOH) provided the title compound (1.75 g, 58%) as a mobile red liquid: ^1H NMR (300 MHz, CDCl_3) δ 5.79 (ddt, $J = 16.8\text{ Hz}, 10.2\text{ Hz}, 6.9\text{ Hz}$, 1H), 5.23 (d, $J = 16.5\text{ Hz}$, 1H), 5.22 (d, $J = 10.5\text{ Hz}$, 1H), 4.28 (t, $J = 7.2\text{ Hz}$, 1H), 2.89 (dt, $J = 14.4\text{ Hz}, 7.2\text{ Hz}$, 1H), 2.76 (dd, $J = 14.4\text{ Hz}, 7.2\text{ Hz}$, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 175.3, 132.5, 119.5, 43.7, 38.6; FTIR (neat, cm^{-1}) 3083, 3000 (broad), 1720, 1430, 1253, 1201, 1171, 993, 927; HRMS (EI) calcd for $\text{C}_5\text{H}_7^{79}\text{BrO}_2$ $[\text{M}]^+$: 177.9629, found: 177.9626.




(*E*)-*t*-Butyl 3-(2-(2-bromo-*N*-(4-methoxybenzyl)pent-4-enamido)-3-methoxyphenyl) acrylate (27a and 27b): To a stirred solution of *rac*-**S6** (0.896 g, 5.00 mmol) in CH_2Cl_2 (20 mL) at $0\text{ }^{\circ}\text{C}$ was added oxalyl chloride (0.635 g, 5.00 mmol) via syringe, followed by catalytic DMF (~1 drop). The mixture was warmed to room temperature and stirred for 2 h. This mixture containing the crude acid chloride was transferred dropwise over 10 min via syringe to a stirred solution of **18c** (0.739 g, 2.00 mmol) in CH_2Cl_2 at $0\text{ }^{\circ}\text{C}$. After 10 min of stirring, Et_3N (0.202 g, 2.00 mmol) was added to this mixture via syringe, and the mixture was stirred at room temperature for 1 h. Saturated aqueous NH_4Cl (35 mL) was added, and the mixture was extracted with CH_2Cl_2 (3 x 35 mL). The combined organic layers were washed with brine (35 mL), dried over MgSO_4 , filtered, and concentrated by rotary evaporation. Column chromatography (4:1 hexanes:EtOAc) provided two diastereomers. The first eluting

diastereomer, *rac*-**27a**, was isolated (0.370 g, 35%) as a clear, colorless oil: ^1H NMR (300 MHz, CDCl_3) δ 7.34 (t, $J = 8.1$ Hz, 1H), 7.12 (d, $J = 7.2$ Hz, 1H), 7.03 (d, $J = 8.4$ Hz, 2H), 6.98 (d, $J = 8.1$ Hz, 1H), 6.95 (d, $J = 15.9$ Hz, 1H), 6.70 (d, $J = 8.4$ Hz, 2H), 6.06 (d, $J = 15.9$ Hz, 1H), 5.60 (ddt, $J = 14.1$ Hz, 9.9 Hz, 7.2 Hz, 1H), 5.40 (d, $J = 13.8$ Hz, 1H), 5.10-5.01 (m, 2H), 4.20 (d, $J = 14.1$ Hz, 1H), 3.83 (s, 3H), 3.79 (t, $J = 7.2$ Hz, 1H), 3.73 (s, 3H), 2.86 (dt, 14.1 Hz, 7.2 Hz, 1H), 2.62 (dt, $J = 14.1$ Hz, 7.2 Hz, 1H), 1.47 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 168.7, 164.9, 159.0, 155.7, 137.7, 134.6, 133.6, 131.1 (2C), 129.7, 127.9, 127.8, 123.0, 118.8, 117.9, 113.4 (2C), 113.0, 80.3, 55.6, 54.9, 51.3, 43.1, 39.7, 27.9 (3C); FTIR (neat, cm^{-1}) 2977, 2936, 2837, 1708, 1666, 1612, 1578, 1513, 1476, 1439, 1393, 1271, 1248, 1152, 1071, 1035, 983, 929, 849, 798; HRMS (ESI) calcd for $\text{C}_{27}\text{H}_{32}^{79}\text{BrNNaO}_5$ $[\text{M} + \text{Na}]^+$: 552.1362, found: 552.1337. The second eluting diastereomer, *rac*-**27b**, was isolated (0.413 g, 39%) as a clear, colorless oil. The racemate was submitted to preparative chiral HPLC separation ((*S,S*)-Whelk-O1, 80:20 hexanes:*i*-PrOH), first eluting enantiomer $[\alpha]_{\text{D}}^{23} +84$, 100/0 er (*c* 3.4 mg/mL, CHCl_3), second eluting enantiomer $[\alpha]_{\text{D}}^{23} -83$, 100/0 er (*c* 4.1 mg/mL, CHCl_3): ^1H NMR (300 MHz, CDCl_3) δ 7.53 (d, $J = 15.9$ Hz, 1H), 7.31 (t, $J = 8.1$ Hz, 1H), 7.22 (d, $J = 7.8$ Hz, 1H), 6.99 (d, $J = 8.7$ Hz, 2H), 6.84 (d, $J = 8.1$ Hz, 1H), 6.68 (d, $J = 8.7$ Hz, 2H), 6.18 (d, $J = 16.2$ Hz, 1H), 5.67 (dddd, $J = 16.8$ Hz, 10.2 Hz, 7.5 Hz, 6.6 Hz, 1H), 5.06 (d, $J = 17.1$ Hz, 1H), 5.05 (d, $J = 9.9$ Hz, 1H), 4.77 (d, $J = 13.8$ Hz, 1H), 4.64 (d, $J = 13.8$ Hz, 1H), 3.89 (t, $J = 7.2$ Hz, 1H), 3.74 (s, 3H), 3.54 (s, 3H), 2.89 (dt, $J = 14.4$ Hz, 6.9 Hz, 1H), 2.68 (dt, $J = 14.4$ Hz, 7.5 Hz, 1H), 1.50 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 169.7, 165.2, 158.9, 155.1, 138.3, 134.5, 134.1, 131.1 (2C), 129.6, 128.1, 127.9, 122.5, 118.8, 117.7, 113.1 (2C), 112.1, 80.3, 55.2, 54.9, 51.7, 43.6, 39.4, 28.0 (3C); FTIR (neat, cm^{-1}) 2977, 2934, 2837, 1707, 1670, 1577, 1513, 1475, 1438, 1394, 1270, 1247,

1152, 1070, 1035, 984, 921, 848, 800, 732; HRMS (ESI) calcd for $C_{27}H_{32}^{79}BrNNaO_5 [M + Na]^+$:
552.1362, found: 552.1349.


Radical Cyclizations of Substrates

Table S.1 Cyclizations of Racemic α -Iodoamides **15a-i**



| entry | α -I | R ¹ | R ² | R ³ | R ⁴ | R ⁵ | cond. ^a | cyc. product | % yield ^b |
|-------|-------------|----------------|----------------|----------------|-----------------------------------|----------------|--------------------|--------------|----------------------|
| 1 | 15a | Me | Me | Me | CO ₂ <i>t</i> -Bu | H | B | 14a | 55 ^d |
| 2 | 15a | Me | Me | Me | CO ₂ <i>t</i> -Bu | H | A | 14a | 83 |
| 3 | 15b | PMB | Me | Me | CO ₂ <i>t</i> -Bu | H | B | 14b | 72 ^d |
| 4 | 15b | PMB | Me | Me | CO ₂ <i>t</i> -Bu | H | A | 14b | 85 |
| 5 | 15c | PMB | OMe | H | CO ₂ <i>t</i> -Bu | H | A | 14c | 97 |
| 6 | 15d | Ts | Me | Me | CO ₂ <i>t</i> -Bu | H | A | 14d | nd ^{c,d} |
| 7 | 15e | PMB | TMS | Me | CO ₂ <i>t</i> -Bu | H | A | 14e | 93 |
| 8 | 15f | PMB | Br | Me | CO ₂ <i>t</i> -Bu | H | A | 14f | 61 |
| 9 | 15g | PMB | Me | Me | 4-BrC ₆ H ₄ | H | B | 14g | nd ^c |
| 10 | 15g | PMB | Me | Me | 4-BrC ₆ H ₄ | H | A | 14g | nd ^c |
| 11 | 15h | PMB | Me | Me | CN | H | A | 14h | < 71 |
| 12 | 15h | PMB | Me | Me | CN | H | C | 14h | 70 |
| 13 | 15i | PMB | Me | Me | Me | Me | A | 14i | 51 ^d |

^a Conditions A: Bu₃SnH and Et₃B in 20 mL PhH were added over 2 h via syringe pump to a stirred 10 mM PhH solution of iodide. B: neat Bu₃SnH and Et₃B were added sequentially in one portion to a stirred PhH solution of iodide with [Bu₃SnH]_i = 10 mM. C: Same as B with [Bu₃SnH]_i = 5 mM. ^b Yield of racemic **14a-i** after isolation by column chromatography on 10% w/w KF/silica gel. ^c nd = not determined. ^d Directly reduced **20a-i** was detected in crude reaction mixture by TLC or ¹H NMR.

Table S.2 Chirality Transfer in Cyclizations of α -Iodoamides **15a-i**


| entry | precursor | R ¹ | R ² | R ³ | R ⁴ | R ⁵ | er | cond. ^a | product | % yield ^b | er | % ct ^d |
|-------|---------------------------------------|----------------|----------------|----------------|------------------------------|----------------|----------|--------------------|---------------------------------------|----------------------|-------|-------------------|
| 1 | (+)- 15a | Me | Me | Me | CO ₂ <i>t</i> -Bu | H | 98.5/1.5 | A | (-)- 14a | 79 | 91/9 | 92 |
| 2 | (-)- 15a | Me | Me | Me | CO ₂ <i>t</i> -Bu | H | 85/15 | A | (+)- 14a | 81 | 84/16 | 99 |
| 3 | (+)- 15b | PMB | Me | Me | CO ₂ <i>t</i> -Bu | H | 100/0 | A | (-)- 14b | 87 | 95/5 | 95 |
| 4 | (-)- 15b | PMB | Me | Me | CO ₂ <i>t</i> -Bu | H | 100/0 | A | (+)- 14b | 85 | 96/4 | 96 |
| 5 | (+)- 15c | PMB | OMe | H | CO ₂ <i>t</i> -Bu | H | 99/1 | A | (-)- 14c | 94 | 93/7 | 94 |
| 6 | (-)- 15c | PMB | OMe | H | CO ₂ <i>t</i> -Bu | H | 99/1 | A | (+)- 14c | 96 | 93/7 | 94 |
| 7 | (+)- 15e | PMB | TMS | Me | CO ₂ <i>t</i> -Bu | H | 100/0 | A | (+)- 14e | 95 | 95/5 | 95 |
| 8 | (-)- 15e | PMB | TMS | Me | CO ₂ <i>t</i> -Bu | H | 100/0 | A | (-)- 14e | 93 | 94/6 | 96 |
| 9 | (<i>P</i>)- 15f ^c | PMB | Br | Me | CO ₂ <i>t</i> -Bu | H | 99/1 | A | (<i>S</i>)- 14f ^c | 63 | 95/5 | 96 |
| 10 | (<i>M</i>)- 15f ^c | PMB | Br | Me | CO ₂ <i>t</i> -Bu | H | 0/100 | A | (<i>R</i>)- 14f ^c | 66 | 94/6 | 94 |
| 11 | (+)- 15h | PMB | Me | Me | CN | H | 99.5/0.5 | C | (-)- 14h | 71 | 93/7 | 93 |
| 12 | (-)- 15h | PMB | Me | Me | CN | H | 99/1 | C | (+)- 14h | 68 | 96/4 | 97 |
| 13 | (+)- 15i | PMB | Me | Me | Me | Me | 99/1 | A | (+)- 14i | 57 | 80/20 | 81 |
| 14 | (-)- 15i | PMB | Me | Me | Me | Me | 0/100 | A | (-)- 14i | 55 | 80/20 | 80 |

^a Conditions A: Bu₃SnH and Et₃B in 20 mL PhH were added over 2 h via syringe pump to a stirred 10 mM PhH solution of iodide. C: neat Bu₃SnH and Et₃B were added sequentially in one portion to a stirred PhH solution of iodide with [Bu₃SnH]_i = 5 mM. ^b Yield of **14a-i** after isolation by column chromatography on 10% w/w KF/silica gel. ^c Absolute stereochemistry determined by X-ray crystallography. ^d Percent chirality transfer.

General procedure “A” for radical cyclizations: Bu₃SnH (0.122 g, 0.42 mmol) and Et₃B (0.35 mL of a 1.0 M hexane solution, 0.35 mmol) were dissolved in degassed benzene (20 mL). This solution was added via syringe pump over a period of 2 h to a stirred solution of the appropriate α -halo amide (0.35 mmol) in benzene (35 mL). Upon completion of the reaction, solvent was removed by rotary evaporation, and the crude residue was directly subjected to flash chromatography on 10% w/w KF/silica gel⁶ using the appropriate eluent.


General procedure “B” for radical cyclizations: Bu₃SnH (0.122 g, 0.42 mmol) and the appropriate α -halo amide (0.35 mmol) were dissolved in a stirred solution of non-degassed benzene (35 mL, 10 mM in Bu₃SnH). Et₃B (0.35 mL of a 1.0 M hexane solution, 0.35 mmol) was added all at once via syringe. Upon completion of the reaction, solvent was removed by rotary evaporation, and the crude residue was directly subjected to flash chromatography on 10% w/w KF/silica gel using the appropriate eluent.

General procedure “C” for radical cyclizations: Bu₃SnH (0.122 g, 0.42 mmol) and the appropriate α -halo amide (0.35 mmol) were dissolved in a stirred solution of non-degassed benzene (70 mL, 5 mM in Bu₃SnH). Et₃B (0.35 mL of a 1.0 M hexane solution, 0.35 mmol) was added all at once via syringe. Upon completion of the reaction, solvent was removed by rotary evaporation, and the crude residue was directly subjected to flash chromatography on 10% w/w KF/silica gel using the appropriate eluent.




***t*-Butyl 2-(1,6,8-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate (14a):** According to general procedure A, **14a** was prepared from the reaction of **15a** and chromatographed eluting with 3:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (75:25 hexanes:*i*-PrOH). *rac*-**15a** yielded *rac*-**14a** as a clear, colorless oil (0.088 g, 83%). The atropisomer (–)-**15a** yielded (+)-**14a** as a clear, colorless oil (0.086 g, 81%), $[\alpha]_D^{23} +6.3$ (*c* 9.6 mg/mL, CHCl₃), 84/16 er, first eluting enantiomer. The atropisomer (+)-**15a** yielded

(-)-**14a** as a clear, colorless oil (0.084 g, 79%), $[\alpha]_D^{23}$ -6.0 (*c* 8.5 mg/mL, CHCl₃), 91/9 er, second eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 6.90 (s, 1H), 6.88 (s, 1H), 3.34 (s, 3H), 3.29 (tt, *J* = 7.5 Hz, 4.8 Hz, 1H), 2.67 (dd, *J* = 15.3 Hz, 4.8 Hz, 1H), 2.54 (dd, *J* = 15.3 Hz, 4.5 Hz, 1H), 2.44 (dd, *J* = 15.3 Hz, 7.5 Hz, 1H), 2.38 (dd, *J* = 15.6 Hz, 7.2 Hz, 1H), 2.33 (s, 3H), 2.27 (s, 3H), 1.45 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.8, 170.7, 138.3, 133.6, 132.3, 131.8, 127.6, 125.3, 80.9, 38.9, 37.8, 35.7, 33.4, 28.0 (3C), 20.6, 20.4; FTIR (neat, cm⁻¹) 2976, 2929, 1728, 1674, 1482, 1426, 1366, 1309, 1256, 1148, 1082, 1039, 961, 859, 844, 733; HRMS (ESI) calcd for C₁₈H₂₅NNaO₃ [M + Na]⁺: 326.1732, found: 326.1756.



***t*-Butyl 2-(1-(4-methoxybenzyl)-6,8-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl) acetate (14b):** According to general procedure A, **14b** was prepared from the reaction of **15b** and chromatographed eluting with 3:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (80:20 hexanes:*i*-PrOH). *rac*-**15b** yielded *rac*-**14b** as a clear, pale yellow oil (0.126 g, 88%). The atropisomer (+)-**15b** yielded (+)-**14b** as a clear, pale yellow oil (0.122 g, 85%), $[\alpha]_D^{23}$ +64 (*c* 9.5 mg/mL, CHCl₃), 96/4 er, first eluting enantiomer. The atropisomer (-)-**15b** yielded (-)-**14b** as a clear, pale yellow oil (0.126 g, 87%), $[\alpha]_D^{23}$ -64 (*c* 16.7 mg/mL, CHCl₃), 95/5 er, second eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 7.07 (d, *J* = 8.4 Hz, 2H), 6.90 (s, 1H), 6.82 (s, 1H), 6.75 (d, *J* = 8.7 Hz, 2H), 5.15 (d, *J* = 14.7 Hz, 1H), 4.87 (d, *J* = 14.7 Hz, 1H), 3.75 (s, 3H), 3.17 (tt, *J* = 7.5 Hz, 5.1 Hz, 1H), 2.63 (dd, *J* = 15.0 Hz, 5.1 Hz, 1H), 2.46 (dd, *J* = 15.0 Hz, 5.1 Hz, 1H), 2.34 (s, 3H), 2.26 (s, 3H), 2.08 (dd, *J* = 15.6 Hz, 7.8


Hz, 1H), 2.01 (dd, $J = 15.6$ Hz, 7.5 Hz, 1H), 1.41 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.1, 170.8, 158.6, 137.1, 133.7, 133.5, 131.8, 129.5, 129.4 (2C), 127.9, 125.5, 113.5 (2C), 80.5, 55.0, 48.6, 38.2, 33.5, 27.9 (3C), 21.0, 20.5, missing peak due to accidental isochrony; FTIR (neat, cm^{-1}) 2976, 2932, 2836, 1727, 1674, 1611, 1513, 1479, 1368, 1248, 1147, 1035, 911, 845, 733; HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{31}\text{NNaO}_4$ $[\text{M} + \text{Na}]^+$: 432.2151, found: 432.2142.




***tert*-Butyl 2-(8-methoxy-1-(4-methoxybenzyl)-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate**

(14c): According to general procedure A, **14c** was prepared from the reaction of **15c** and chromatographed eluting with 2:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (50:50 hexanes:*i*-PrOH). *rac*-**15c** yielded *rac*-**14c** as a clear, colorless oil (0.140 g, 97%). The atropisomer (–)-**15c** yielded (+)-**14c** as a clear, colorless oil (0.138 g, 96%), $[\alpha]_{\text{D}}^{23} +86$ (*c* 4.1 mg/mL, CHCl_3), 93/7 er, first eluting enantiomer. The atropisomer (+)-**15c** yielded (–)-**14c** as a clear, colorless oil (0.136 g, 94%), $[\alpha]_{\text{D}}^{23} -87$ (*c* 7.3 mg/mL, CHCl_3), 93/7 er, second eluting enantiomer: ^1H NMR (300 MHz, CDCl_3) δ 7.11 (d, $J = 8.7$ Hz, 2H), 7.01 (t, $J = 7.8$ Hz, 1H), 6.81 (d, $J = 8.4$ Hz, 1H), 6.79 (d, $J = 7.8$ Hz, 1H), 6.74 (d, $J = 8.7$ Hz, 2H), 5.38 (d, $J = 14.4$ Hz, 1H), 5.22 (d, $J = 14.7$ Hz, 1H), 3.81 (s, 3H), 3.74 (s, 3H), 3.27 (m, 1H), 2.70 (dd, $J = 15.0$ Hz, 5.1 Hz, 1H), 2.54 (dd, $J = 15.0$ Hz, 4.8 Hz, 1H), 2.22 (dd, $J = 15.9$ Hz, 7.8 Hz, 1H), 2.17 (dd, $J = 16.2$ Hz, 7.8 Hz, 1H), 1.40 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.8, 170.7, 158.4, 149.9, 133.9, 130.4, 129.3 (2C), 128.1, 124.7, 119.6, 113.3 (2C), 111.5, 80.7, 55.5, 55.0, 46.7, 38.2, 37.7, 33.4, 28.0 (3C); FTIR (neat, cm^{-1}) 2976, 2936, 2837,


2248, 1727, 1674, 1612, 1589, 1513, 1484, 1462, 1368, 1248, 1148, 1102, 1033, 912, 845, 784, 733; HRMS (ESI) calcd for C₂₄H₂₉NNaO₅ [M + Na]⁺: 434.1943, found: 434.1945.



***tert*-Butyl 2-(1-(4-methoxybenzyl)-6-methyl-2-oxo-8-(trimethylsilyl)-1,2,3,4-tetrahydroquinolin-4-yl) acetate (14e):** According to general procedure A, **14e** was prepared from the reaction of **15e** and chromatographed eluting with 3:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (80:20 hexanes:*i*-PrOH). *rac*-**15e** yielded *rac*-**14e** as a clear, colorless oil (0.152 g, 93%). The atropisomer (+)-**15e** yielded (+)-**14e** as a clear, colorless oil (0.155 g, 95%), [α]_D²³ +122 (*c* 4.8 mg/mL, CHCl₃), 95/5 er, first eluting enantiomer. The atropisomer (–)-**15e** yielded (–)-**14e** as a clear, colorless oil (0.152 g, 93%), [α]_D²³ –120 (*c* 15.2 mg/mL, CHCl₃), 94/6 er, second eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 7.29 (d, *J* = 1.8 Hz, 1H), 7.02 (d, *J* = 8.7 Hz, 2H), 6.97 (d, *J* = 1.8 Hz, 1H), 6.71 (d, *J* = 8.7 Hz, 2H), 5.34 (d, *J* = 13.5 Hz, 1H), 4.69 (d, *J* = 13.5 Hz, 1H), 3.73 (s, 3H), 3.08 (m, 1H), 2.59 (dd, *J* = 15.0 Hz, 5.1 Hz, 1H), 2.41 (dd, *J* = 15.0 Hz, 4.2 Hz, 1H), 2.31 (s, 3H), 1.73 (m, 2H), 0.41 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.0, 170.9, 158.9, 143.5, 136.0, 133.1, 132.6, 130.3, 130.2 (2C), 129.1, 129.0, 113.5 (2C), 80.3, 55.0, 51.7, 37.9, 37.8, 33.4, 27.9 (3C), 20.7, 0.6 (3C); FTIR (thin film, CHCl₃, cm^{–1}) 2975, 2836, 1727, 1675, 1611, 1513, 1452, 1368, 1249, 1151, 1112, 1037, 922, 864, 838, 757; HRMS (ESI) calcd for C₂₇H₃₇NNaO₄Si [M + Na]⁺: 490.2390, found: 490.2409.




tert-Butyl 2-(8-bromo-1-(4-methoxybenzyl)-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate (14f): According to general procedure A, **14f** was prepared from the reaction of **15f** and chromatographed eluting with 3:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (70:30 hexanes:*i*-PrOH). *rac*-**15f** yielded *rac*-**14f** as a clear, colorless oil (0.102 g, 61%). The atropisomer (+)-**15f** yielded (+)-**14f** as a white solid (0.104 g, 63%), $[\alpha]_D^{23} +100$ (*c* 7.0 mg/mL, CHCl₃), 95/5 er, first eluting enantiomer. The atropisomer (–)-**15f** yielded (–)-**14f** as a clear, colorless oil (0.109 g, 66%), $[\alpha]_D^{23} -100$ (*c* 10.3 mg/mL, CHCl₃), 96/4 er, second eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 7.34 (s, 1H), 7.11 (d, *J* = 8.7 Hz, 2H), 6.93 (s, 1H), 6.74 (d, *J* = 8.4 Hz, 2H), 5.42 (d, *J* = 14.7 Hz, 1H), 5.34 (d, *J* = 15.3 Hz, 1H), 3.74 (s, 3H), 3.15 (m, 1H), 2.62 (dd, *J* = 15.0 Hz, 4.8 Hz, 1H), 2.47 (dd, *J* = 15.0 Hz, 5.1 Hz, 1H), 2.27 (s, 3H), 1.97 (d, *J* = 7.5 Hz, 2H), 1.39 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.5, 170.5, 158.8, 136.3, 135.5, 133.9, 130.2 (2C), 129.3, 127.3, 113.5, 113.4 (2C), 80.7, 55.0, 47.5, 38.0, 37.7, 33.6, 27.9 (3C), 20.3, missing peak due to accidental isochrony; FTIR (neat, cm⁻¹) 2977, 2932, 2836, 1725, 1685, 1611, 1513, 1467, 1366, 1302, 1248, 1153, 1035, 917, 827, 761, 734; HRMS (ESI) calcd for C₂₄H₂₈⁷⁹BrNNaO₄ [M + Na]⁺: 496.1099, found: 496.1104.




2-(1-(4-Methoxybenzyl)-6,8-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetonitrile

(14h): According to general procedure C, **14f** was prepared from the reaction of **15f** and chromatographed eluting with 3:2 hexanes:EtOAc. The fractions containing the desired product were collected and concentrated, and a second flash column (silica gel only) was performed, eluting with 3:2 hexanes:EtOAc to remove residual impurities. The products were ~95% pure by ^1H NMR, containing trace unidentifiable impurities. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (80:20 hexanes:EtOAc). *rac*-**15h** yielded *rac*-**14h** as a white solid (0.082 g, 70%), mp 101-102 °C. The atropisomer (-)-**15h** yielded (+)-**14h** as a white solid (0.080 g, 68%), $[\alpha]_{\text{D}}^{23}$ +99 (*c* 19.8 mg/mL, CHCl_3), 96/4 er, first eluting enantiomer. The atropisomer (+)-**15h** yielded (-)-**14h** as a white solid (0.083 g, 71%), $[\alpha]_{\text{D}}^{23}$ -97 (*c* 4.5 mg/mL, CHCl_3), 93/7 er, second eluting enantiomer: ^1H NMR (300 MHz, CDCl_3) δ 7.03 (s, 1H), 6.87 (s, 1H), 7.02 (d, *J* = 8.4 Hz, 2H), 6.76 (d, *J* = 8.7 Hz, 2H), 5.25 (d, *J* = 14.4 Hz, 1H), 4.73 (d, *J* = 14.4 Hz, 1H), 3.75 (s, 3H), 2.97 (m, 1H), 2.71 (dd, *J* = 15.3 Hz, 4.8 Hz, 1H), 2.50 (dd, *J* = 15.3 Hz, 4.2 Hz, 1H), 2.41 (s, 3H), 2.33 (s, 3H), 2.03 (dd, *J* = 16.8 Hz, 6.6 Hz, 1H), 1.75 (dd, *J* = 16.8 Hz, 9.0 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 170.7, 159.0, 136.8, 134.5, 132.8, 130.7, 129.8 (2C), 129.1, 128.5, 125.9, 117.5, 113.7 (2C), 55.1, 48.6, 37.7, 34.0, 20.8, 20.6, 20.3; FTIR (thin film, CHCl_3 , cm^{-1}) 3012, 2959, 2837, 1673, 1513, 1479, 1376, 1249, 1176, 1033, 859, 757; HRMS (ESI) calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{NaO}_2$ $[\text{M} + \text{Na}]^+$: 357.1579, found: 357.1612.




4-Isopropyl-1-(4-methoxybenzyl)-6,8-dimethyl-3,4-dihydroquinolin-2(1H)-one (**14i**):

According to general procedure A, **14i** was prepared from the reaction of **15i** and chromatographed eluting with 3:1 pentane:Et₂O. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (80:20 hexanes:*i*-PrOH). *rac*-**15i** yielded *rac*-**14i** as a clear, colorless oil (0.060 g, 51%). The atropisomer (–)-**15i** yielded (–)-**14i** as a clear, colorless oil (0.065 g, 55%), $[\alpha]_D^{23} -44$ (*c* 6.3 mg/mL, CHCl₃), 80/20 er, second eluting enantiomer. The atropisomer (+)-**15i** yielded (+)-**14i** as a clear, colorless oil (0.067 g, 57%), $[\alpha]_D^{23} +44$ (*c* 8.6 mg/mL, CHCl₃), 80/20 er, first eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 7.04 (d, *J* = 8.7 Hz, 2H), 6.90 (s, 1H), 6.73 (d, *J* = 8.7 Hz, 2H), 6.71 (s, 1H), 5.22 (d, *J* = 14.7 Hz, 1H), 4.74 (d, *J* = 14.7 Hz, 1H), 3.75 (s, 3H), 2.65 (dd, *J* = 15.0 Hz, 3.6 Hz, 1H), 2.54 (dd, *J* = 14.7 Hz, 4.8 Hz, 1H), 2.33 (s, 3H), 2.28 (s, 3H), 2.19 (dt, *J* = 9.3 Hz, 4.2 Hz, 1H), 1.06 (d of septets, *J* = 9.3 Hz, 6.6 Hz, 2.7 Hz, 1H), 0.84 (d, *J* = 6.6 Hz, 3H), 0.66 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 172.9, 158.6, 137.3, 134.8, 133.2, 131.3, 129.7, 129.5 (2C), 128.1, 127.3, 113.3 (2C), 55.2, 48.6, 44.8, 36.3, 28.2, 21.5, 21.1, 20.6, 19.8; FTIR (neat, cm⁻¹) 2957, 2868, 2835, 1673, 1611, 1513, 1477, 1365, 1295, 1247, 1177, 1162, 1112, 1035, 860, 812; HRMS (ESI) calcd for C₂₂H₂₇NNaO₂ [M + Na]⁺: 360.1939, found: 360.1911.




***trans-tert*-Butyl 2-(8-methoxy-1-(4-methoxybenzyl)-3-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-4-yl)acetate (26):** According to general procedure A, **26** was prepared from the reaction of **25b** and chromatographed eluting with 2:1 hexanes:EtOAc. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (70:30 hexanes:*i*-PrOH). *rac*-**25b** yielded *rac*-**26** as a clear, colorless oil (0.145 g, 97%). The atropisomer (+)-**25b** yielded (–)-**26** as a clear, colorless oil (0.146 g, 98%), $[\alpha]_{\text{D}}^{23} -109$ (*c* 13.2 mg/mL, CHCl₃), 99/1 er, second eluting enantiomer. The atropisomer (–)-**25b** yielded (+)-**26** as a clear, colorless oil (0.145 g, 97%), $[\alpha]_{\text{D}}^{23} +111$ (*c* 20.4 mg/mL, CHCl₃), 99.5/0.5 er, first eluting enantiomer: ¹H NMR (300 MHz, CDCl₃) δ 7.12 (d, *J* = 8.7 Hz, 2H), 7.01 (t, *J* = 8.4 Hz, 1H), 6.82 (d, *J* = 8.4 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 1H), 6.75 (d, *J* = 8.7 Hz, 2H), 5.41 (d, *J* = 14.4 Hz, 1H), 5.17 (d, *J* = 14.7 Hz, 1H), 3.79 (s, 3H), 3.74 (s, 3H), 2.97 (m with clear d, *J* = 2.7 Hz, 1H), 2.68 (qd, *J* = 7.2 Hz, 2.7 Hz, 1H), 2.21 (dd, *J* = 15.6 Hz, 6.9 Hz, 1H), 2.10 (dd, *J* = 15.6 Hz, 8.1 Hz, 1H), 1.38 (s, 9H), 1.05 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 173.6, 170.7, 158.3, 149.5, 131.2, 130.6, 129.2 (2C), 127.1, 124.7, 121.5, 113.2 (2C), 111.7, 80.5, 55.4, 54.9, 46.7, 41.8, 40.4, 39.0, 27.9 (3C), 14.9; FTIR (thin film, CHCl₃, cm⁻¹) 2974, 2934, 2837, 1727, 1669, 1612, 1590, 1512, 1483, 1461, 1365, 1248, 1175, 1150, 1107, 1085, 1036, 976, 935, 846, 790, 740; HRMS (ESI) calcd for C₂₅H₃₁NNaO₅ [*M* + Na]⁺: 448.2100, found: 448.2128.




(±)-(1*S*,2*S*,3*aR*,9*bS*)-*t*-Butyl 6-methoxy-5-(4-methoxybenzyl)-2-methyl-4-oxo-2,3,3*a*,4,5,9*b*-hexahydro-1*H*-cyclopenta[*c*]quinoline-1-carboxylate (28): According to general procedure A,

28 was prepared from the reaction of **27a-b** (0.143 g, 0.270 mmol) and chromatographed eluting with 3:1 hexanes:EtOAc on 10% w/w KF/silica. A second flash column was run with 3:2 pentane:Et₂O on silica only to remove residual impurities. Chiral analysis was performed on the analytical (*S,S*)-Whelk-O1 column (60:40 hexanes:*i*-PrOH). *rac*-**27a** yielded *rac*-**28** as a clear, colorless solid (0.062 g, 51%, > 95% diastereomeric purity). The atropisomer (+)-**27b** yielded (-)-**28** as a clear, colorless oil (0.062 g, 51%, ~95% diastereomeric purity), $[\alpha]_D^{23} -113$ (*c* 12.3 mg/mL, CHCl₃), 99/1 er, first eluting enantiomer. The atropisomer (-)-**27b** yielded (+)-**28** as a clear, colorless solid, (0.060 g, 49%, ~95% diastereomeric purity), $[\alpha]_D^{23} +110$ (*c* 10.4 mg/mL, CHCl₃), 98/2 er, second eluting enantiomer: ¹H NMR (75 MHz, CDCl₃) δ 7.07 (d, *J* = 8.7 Hz, 2H), 7.00 (t, *J* = 7.5 Hz, 1H), 6.76 (d, *J* = 7.8 Hz, 1H), 6.73 (d, *J* = 8.7 Hz, 2H), 6.53 (d, *J* = 7.5 Hz, 1H), 5.51 (d, *J* = 15.0 Hz, 1H), 5.01 (d, *J* = 15.0 Hz, 1H), 3.77 (s, 3H), 3.73 (s, 3H), 3.30 (dd, *J* = 14.1 Hz, 10.8 Hz, 1H), 2.89 (t, *J* = 10.8 Hz, 1H), 2.69 (d of sextets, *J* = 10.5 Hz, 7.2 Hz, 1H), 2.40 (ddd, *J* = 14.4 Hz, 11.1 Hz, 7.2 Hz, 1H), 2.30 (dt, *J* = 12.6 Hz, 7.2 Hz, 1H), 1.68 (m, 1H), 1.51 (s, 9H), 1.10 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 173.3, 172.4, 158.2, 149.9, 135.3, 130.9, 129.1, 128.4 (2C), 125.0, 116.2, 113.4 (2C), 111.1, 80.9, 55.4, 55.0, 50.7, 46.9, 46.8, 44.2, 35.1, 33.7, 28.1 (3C), 18.2; FTIR (thin film, CHCl₃, cm⁻¹) 2971, 2837, 1724, 1678, 1513, 1459, 1368, 1280, 1247, 1148, 1067, 1036, 800, 763; HRMS (ESI) calcd for C₂₇H₃₃NNaO₅ [M + Na]⁺: 474.2256, found: 474.2293.


Synthesis of Other Compounds



(E)-tert-Butyl 3-(2-(N-(4-methoxybenzyl)acetamido)-3,5-dimethylphenyl)acrylate (20b): To a stirred solution of **18b** (0.147 g, 0.400 mmol) and Et₃N (0.080 g, 0.800 mmol) in CH₂Cl₂ (4.0 mL) at 0 °C was added acetyl chloride (0.047 g, 0.600 mmol) dropwise via syringe. The mixture was stirred at this temperature for 15 min, and saturated aqueous NH₄Cl solution (5 mL) was added. The mixture was extracted with CH₂Cl₂ (3 x 5 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (2:1 hexanes:EtOAc) provided the title compound (0.150 g, 92%) as a clear, colorless oil: ¹H NMR (300 MHz, CDCl₃) δ 7.26 (s, 1H), 7.17 (d, *J* = 15.9 Hz, 1H), 7.07 (s, 1H), 7.05 (d, *J* = 8.7 Hz, 1H), 7.72 (d, *J* = 8.4 Hz, 1H), 6.13 (d, *J* = 15.9 Hz, 1H), 4.83 (d, *J* = 13.8 Hz, 1H), 4.55 (d, *J* = 13.5 Hz, 1H), 3.76 (s, 3H), 2.34 (s, 3H), 1.91 (s, 3H), 1.72 (s, 3H), 1.50 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 170.3, 165.4, 159.0, 138.4, 138.0, 137.5, 136.6, 133.6, 133.0, 131.3 (2C), 128.4, 125.5, 122.0, 113.5 (2C), 80.3, 55.0, 51.2, 28.0 (3C), 22.0, 21.0, 17.5; FTIR (neat, cm⁻¹) 2977, 2931, 2836, 1708, 1659, 1612, 1512, 1471, 1391, 1326, 1247, 1151, 1035, 984, 851, 731; HRMS (ESI) calcd for C₂₅H₃₁NNaO₄ [M + Na]⁺: 432.2151, found: 432.2149.



rac-(E)-tert-Butyl 3-(3,5-dimethyl-2-(N-tosylacetamido)phenyl)acrylate (20d): To a stirred solution of **18d** (0.402 g, 1.00 mmol) and Et₃N (0.202 g, 2.00 mmol) in CH₂Cl₂ (5.0 mL) at 0 °C was added AcCl (0.118 g, 1.50 mmol) dropwise via syringe. The reaction mixture was stirred at this temperature for 30 min, and saturated aqueous NH₄Cl solution (10 mL) was added. The mixture was extracted with CH₂Cl₂ (3 x 10 mL), and the combined organic layers were washed with brine (10 mL), dried over MgSO₄, filtered, and concentrated by rotary evaporation. Column chromatography (3:1 hexanes:EtOAc) furnished the title compound (0.400 g, 90%) as a flaky white solid, mp 144-145 °C: ¹H NMR (300 MHz, CDCl₃) δ 7.99 (d, *J* = 8.4 Hz, 2H), 7.41 (s, 1H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.31 (d, *J* = 16.2 Hz, 1H), 7.23 (s, 1H), 6.37 (d, *J* = 15.6 Hz, 1H), 2.45 (s, 3H), 2.40 (s, 3H), 2.39 (s, 3H), 1.78 (s, 3H), 1.47 (9H); ¹³C NMR (75 MHz, CDCl₃) δ 169.5, 164.8, 144.8, 139.8, 139.1, 137.8, 135.0, 133.7 (2C, accidental isochrony), 132.6, 129.9 (2C), 129.0 (2C), 125.5, 123.1, 80.2, 27.7 (3C), 23.9, 21.4, 20.9, 18.6; FTIR (thin film, CHCl₃, cm⁻¹) 2978, 2929, 1709, 1635, 1366, 1332, 1258, 1169, 1086, 1011, 983, 881, 853, 814, 756; HRMS (ESI) calcd for C₂₄H₂₉NNaO₅S [M + Na]⁺: 466.1664, found: 466.1634.

**(P)-(E)-3-(3-Bromo-2-(2-iodo-N-(4-methoxybenzyl)acetamido)-5-methylphenyl)acrylic acid**

(24): To a stirred solution of (+)-**15f** (0.284 g, 0.473 mmol, 99/1 er) in CH₂Cl₂ (2.0 mL) at room temperature was added trifluoroacetic acid (2.0 mL) via syringe all at once. The reaction mixture was stirred for 1 h, at which point solvent was removed by rotary evaporation. The crude residue was directly subjected to column chromatography (40:60:1 hexanes:EtOAc:AcOH) to furnish the title compound (0.183 g, 71%) as a pale yellow solid, mp 109-110 °C, [α]_D²³ +21, 99/1 er (*c* 14.9 mg/mL, CHCl₃): ¹H NMR (300 MHz, CDCl₃) δ 7.59 (s, 1H), 7.36 (s, 1H), 7.26 (d, *J* = 15.9 Hz, 1H), 7.04 (d, *J* = 8.4 Hz, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 6.07 (d, *J* = 15.9 Hz, 1H), 5.38 (d, *J* = 14.1 Hz, 1H), 4.21 (d, *J* = 14.1 Hz, 1H), 3.75 (s, 3H), 3.60 (d, *J* = 10.5 Hz, 1H), 3.43 (d, *J* = 10.8 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 170.6, 167.7, 159.4, 140.8 (2C, accidental isochrony), 136.1, 136.0, 135.0, 131.5 (2C), 127.2, 126.8, 124.7, 120.1, 113.8 (2C), 55.1, 52.1, 20.9, -2.6; FTIR (thin film, CHCl₃, cm⁻¹) 2999 (broad), 2836, 1693, 1662, 1512, 1461, 1383, 1320, 1283, 1250, 1176, 1106, 1034, 982, 910, 851, 822, 732; HRMS (ESI) calcd for C₂₀H₁₉⁷⁹BrINNaO₄ [M + Na]⁺: 565.9440, found: 565.9465.

Analysis of *N*-Aryl Bond Rotation Barriers



The appropriate compound (enantiomerically enriched in the second eluting enantiomer) was dissolved in a 9:1 hexanes:iPrOH solvent mixture to make a ~2 mg/mL solution in a sealable tube. The tube was sealed and placed in a pre-equilibrated oil bath with electronic temperature controller. At various time intervals, the sealed tube was removed briefly (1-2 minutes) from the bath, cracked, and a 10 μ L aliquot was removed via syringe and injected onto the appropriate analytical HPLC column to measure the enantiomeric ratio. This ratio was plotted against time, and the barrier to rotation was calculated from the plot.⁷ In the y-axis of the plot, “F” denotes the fraction of the first eluting enantiomer, and “S” denotes the fraction of the second eluting enantiomer. The half-life for racemization at ambient temperature is determined by first calculating the rate of racemization (k_{rac}) from the barrier to rotation at 25 °C, assuming that $\Delta G_{rot}^{\ddagger}$ is mostly constant over a large temperature range.

$$k_{rac} = 2k_{rot} = \frac{2k_B T}{h} e^{\left(\frac{-\Delta G_{rot}^{\ddagger}}{RT}\right)} \quad t_{1/2} = \frac{\ln 2}{k_{rac}}$$

A sample full data treatment is shown for **15b**.

Analysis of **15b**:

| time (min) | % ee |
|------------|------|
| 0 | 99.7 |
| 39 | 95.6 |
| 90 | 93.4 |
| 190 | 89.5 |
| 276 | 81.8 |
| 367 | 80.3 |
| 481 | 72.5 |
| 575 | 66.4 |
| 670 | 62.1 |



Equation for racemization: $\ln \left[\frac{1 + [F - 15b]/[S - 15b]}{1 - [F - 15b]/[S - 15b]} \right] = k_{rac} t + c = 2k_{rot} t + c$

Corresponding plot: $\ln \left[\frac{1 + [F - 15b]/[S - 15b]}{1 - [F - 15b]/[S - 15b]} \right]$ vs. time, where slope = $2k_{rot}$

$$k_{rot} = \frac{\text{slope}}{2} = \frac{1.147 \times 10^{-5} \text{ s}^{-1}}{2} = 5.735 \times 10^{-6} \text{ s}^{-1}$$

$$K_{rot}^{\ddagger} = \frac{k_{rot} h}{kT} = \frac{(5.735 \times 10^{-5} \text{ s}^{-1})(6.626 \times 10^{-34} \text{ J} \cdot \text{s})}{(1.381 \times 10^{-23} \text{ J/K})(388 \text{ K})} = 6.66 \times 10^{-19}$$

$$\Delta G_{rot}^{\ddagger} = -RT \ln K_{rot}^{\ddagger} = -(0.0083145 \text{ kJ/mol})(388 \text{ K}) \ln(6.66 \times 10^{-19}) = 143.72 \text{ kJ/mol} = 34.3 \text{ kcal/mol}$$



$$k_{rot} = 5.74 \times 10^{-6} \text{ s}^{-1}$$

$$\Delta G_{rot}^{\ddagger} = 34.3 \text{ kcal/mol}$$

$$t_{1/2} \text{ at } 25 \text{ }^{\circ}\text{C} = 27,500 \text{ years}$$

Analysis of **15c**:

| time (min) | % ee |
|------------|------|
| 0 | 96.2 |
| 22 | 91.3 |
| 57 | 82.9 |
| 125 | 69.1 |
| 201 | 56.2 |
| 284 | 46.1 |
| 378 | 35.8 |
| 489 | 27.7 |





$$k_{\text{rot}} = 2.14 \times 10^{-5} \text{ s}^{-1}$$

$$\Delta G_{\text{rot}}^{\ddagger} = 26.3 \text{ kcal/mol}$$

$$t_{1/2} \text{ at } 25 \text{ }^{\circ}\text{C} = 12 \text{ days}$$

Analysis of **15f**:

| time (min) | % ee |
|------------|------|
| 0 | 99.5 |
| 23 | 95.3 |
| 63 | 91.9 |
| 133 | 86.3 |
| 200 | 76.2 |
| 274 | 71.1 |
| 348 | 66.7 |
| 397 | 60.7 |
| 469 | 57.4 |





$$k_{\text{rot}} = 9.85 \times 10^{-6} \text{ s}^{-1}$$

$$\Delta G_{\text{rot}}^{\ddagger} = 34.2 \text{ kcal/mol}$$

$$t_{1/2} \text{ at } 25 \text{ }^{\circ}\text{C} = 19,900 \text{ years}$$

Analysis of **19c**:

| time (min) | % ee |
|------------|------|
| 0 | 94.1 |
| 9 | 91.1 |
| 29 | 77.1 |
| 49 | 65.9 |
| 86 | 47.9 |
| 122 | 35.1 |
| 172 | 23.5 |
| 232 | 14.4 |




$$k_{\text{rot}} = 6.85 \times 10^{-5} \text{ s}^{-1}$$


$$\Delta G_{\text{rot}}^{\ddagger} = 25.3 \text{ kcal/mol}$$



$$t_{1/2} \text{ at } 25\text{ }^\circ\text{C} = 2.2 \text{ days}$$


References

1. Skoog, D. A.; Holler, F. J.; Nieman, T. A. *Principles of Instrumental Analysis*; 5th ed.; Harcourt Brace College Publishers: Philadelphia, 1998.
2. Adams, R.; Sundholm, N. K. *J. Am. Chem. Soc.* **1948**, *70*, 2667-2673.
3. Guthrie, D. B.; Curran, D. P. *Org. Lett.* **2009**, *11*, 249-251.
4. Nakamura, I.; Yamagishi, U.; Song, D.; Konta, S.; Yamamoto, Y. *Angew. Chem. Int. Ed.* **2007**, *46*, 2284-2287.
5. Petit, M.; Geib, S. J.; Curran, D. P. *Tetrahedron* **2004**, *60*, 7543-7552.
6. Harrowven, D. C.; Guy, I. L. *Chem. Commun.* **2004**, 1968-1969.
7. Eliel, E. L.; Wilen, S. H. *Stereochemistry of Organic Compounds*; John Wiley & Sons, Inc.: New York, 1994.













| | |
|--------|---|
| 158.71 | — |
| 145.18 | — |
| 136.98 | — |
| 133.91 | — |
| 132.31 | — |
| 131.64 | — |
| 131.32 | — |
| 129.26 | — |
| 113.68 | — |
| 96.20 | — |
| 77.43 | — |
| 77.00 | — |
| 76.58 | — |
| 55.04 | — |
| 52.11 | — |
| 19.92 | — |
| 19.44 | — |












S2



| Chemical Shift (ppm) |
|----------------------|
| 158.56 |
| 151.20 |
| 138.96 |
| 132.11 |
| 131.19 |
| 129.27 |
| 123.06 |
| 113.55 |
| 111.44 |
| 92.29 |
| 77.42 |
| 77.00 |
| 76.58 |
| 55.67 |
| 55.06 |
| 51.42 |


























S5
















18b







18c









18d


28.13
21.55
21.01
18.82

80.29
77.43
77.00
76.58


143.50
139.26
138.97
137.89
136.32
133.85
133.60
130.48
129.60
127.45
125.19
120.47


165.82

ppm
0
20
40
60
80
100
120
140
160
180
200





18e






18e







18f


282





18f






18g

7.809
 7.753
 7.270
 7.189
 7.180
 7.173
 7.158
 7.151
 7.142
 7.104
 7.021
 6.893
 6.883
 6.876
 6.861
 6.854
 6.845
 5.883
 5.827


4.009
 3.820
 3.267

2.285
 2.091





9.5
 9.0
 8.5
 8.0
 7.5
 7.0
 6.5
 6.0
 5.5
 5.0
 4.5
 4.0
 3.5
 3.0
 2.5
 2.0
 1.5
 1.0
 ppm


0.96
 2.06
 1.00
 1.05
 2.00
 0.97
 3.00
 0.92
 0.15
 2.96
 0.13
 3.02




18g








158.81
 143.21
 136.94
 132.63
 131.64
 131.53
 131.07
 129.86
 129.71
 128.99
 127.80
 127.25
 127.15
 125.28
 120.79
 113.88
 77.43
 77.00
 76.58
 59.22
 54.07
 20.75
 17.93











1.724
 1.728
 1.875
 1.880
 2.249
 2.258


3.331
 3.811
 4.025

6.150
 6.788
 6.838
 6.848
 6.854
 6.869
 6.877
 6.886
 7.213
 7.222
 7.229
 7.245
 7.251
 7.261













19a






19b





19b

| | | |
|--------|--------|--------|
| 165.55 | 164.74 | 158.96 |
| 138.59 | 137.40 | 136.28 |
| 135.11 | 133.57 | 132.82 |
| 131.05 | 127.06 | 125.42 |
| 122.22 | 113.34 | |
| 79.97 | 77.42 | 77.00 |
| 76.57 | | |
| 54.60 | 51.97 | 41.64 |
| 27.62 | 20.65 | 17.24 |




1.503

3.788
3.737
3.688
3.635

4.872
4.826
4.651
4.605

7.326
7.299
7.269
7.213
7.195
7.169
7.020
6.992
6.919
6.891
6.705
6.677
6.207
6.154



9.37

4.93
2.87

1.09
0.98


0.99

2.00
1.02



2.20
1.02
2.02


1.15

7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm





19c







19d







19d











19e







19f








19f






19g










199

- 166.47
- 159.34
- 138.83
- 136.08
- 135.55
- 135.35
- 134.91
- 131.96
- 131.54
- 131.50
- 129.84
- 128.22
- 128.10
- 124.51
- 124.13
- 121.72
- 113.74
- 77.42
- 77.00
- 76.57
- 58.01
- 52.59
- 42.28
- 21.16
- 17.80













19i





19i






1.519


2.200
2.260
2.317
2.364

3.169
3.282
3.423
3.457
3.463
3.497
3.865
3.897
3.946
3.978


6.315
6.328
6.368
6.381




7.088
7.151
7.270
7.308
7.354
7.356
7.519
7.572







15a













15b














15d






15d







15f

1.481

2.378

3.418

3.453

3.564

3.600

3.743

4.233

4.279

5.246

5.293

5.986

6.039

6.675

6.684

6.690

6.706

6.713

6.722

6.994

7.003

7.010

7.026

7.032

7.041

7.082

7.135

7.269

9.43

3.00

0.97

1.02

2.95

0.97

0.98

0.99


2.00


2.07

1.07


0.96


0.87







15f








15g










15g










15h







25a

1.704
1.682
1.455

4.177
4.131
4.040
4.018
3.996
3.973
3.842
3.732

7.128
7.102
7.046
7.039
7.024
7.017
6.988
6.927
6.874
6.719
6.709
6.702
6.687
6.680
6.670
6.089
6.036
5.447
5.401

2.96
9.36

0.98
1.04
3.00
3.02



0.99


1.00

2.03

1.11
3.21
1.06
1.08









1.746
 1.724
 1.506


4.847
 4.801
 4.587
 4.541
 4.144
 4.122
 4.099
 4.078
 3.737
 3.534


7.341
 7.314
 7.287
 7.269
 7.241
 7.214
 6.992
 6.963
 6.862
 6.836
 6.693
 6.665
 6.228
 6.175






25b









S6

5.859
5.836
5.825
5.814
5.802
5.780
5.768
5.757
5.746
5.723
5.258
5.253
5.233
5.198
4.308
4.284
4.259
2.942
2.918
2.894
2.870
2.846
2.804
2.781
2.757
2.732
2.709












27a







27b

7.229
7.203
7.000
6.971
6.851
6.824
6.696
6.667
6.203
6.149
5.740
5.715
5.706
5.693
5.684
5.659
5.649
5.637
5.628
5.625
5.603
5.091
5.067
5.034
4.796
4.750
4.662
4.616
3.911
3.887
3.863
3.738
3.543
2.941
2.918
2.893
2.870
2.849
2.732
2.706
2.681
2.658
2.633
1.501






27b





1.447
 2.269
 2.326
 2.345
 2.370
 2.397
 2.402
 2.422
 2.427
 2.454
 2.479
 2.505
 2.521
 2.556
 2.571
 2.633
 2.650
 2.684
 2.700
 3.255
 3.271
 3.280
 3.287
 3.296
 3.305
 3.312
 3.321
 3.341

6.878
 6.903




14a







14a




7.270
 7.086
 7.058
 6.904
 6.824
 6.775
 6.775
 6.765
 6.758
 6.743
 6.736
 6.726
 5.170
 5.121
 4.892
 4.843
 3.749
 3.212
 3.195
 3.187
 3.170
 3.153
 3.145
 3.128
 2.664
 2.647
 2.614
 2.597
 2.497
 2.480
 2.447
 2.430
 2.343
 2.260
 2.128
 2.115
 2.089
 2.063
 2.053
 2.037
 2.028
 2.001
 1.977
 1.405





14b





14b







1.403
 2.128
 2.154
 2.182
 2.208
 2.261
 2.507
 2.523
 2.557
 2.573
 2.666
 2.683
 2.716
 2.733
 3.232
 3.248
 3.257
 3.273
 3.290
 3.298
 3.315
 3.739
 3.811


 5.191
 5.240
 5.355
 5.403


 6.724
 6.753
 6.774
 6.800
 6.828
 6.979
 7.005
 7.031
 7.100
 7.129
 7.269







14c







14e







14f



7.336
7.271
7.122
7.115
7.093
6.931
6.749
6.743
6.721
6.711
5.442
5.393
5.362
5.311
3.744
3.196
3.178
3.170
3.154
3.137
3.129
3.112
2.650
2.634
2.600
2.584
2.501
2.484
2.451
2.434
2.272
1.986
1.961
1.393







14f











14h







14i









- 7.270
- 7.133
- 7.104
- 7.034
- 7.006
- 6.981
- 6.837
- 6.809
- 6.785
- 6.782
- 6.761
- 6.732
- 5.430
- 5.382
- 5.198
- 5.149
- 3.790
- 3.743
- 3.004
- 2.995
- 2.974
- 2.954
- 2.945
- 2.721
- 2.713
- 2.697
- 2.688
- 2.673
- 2.664
- 2.649
- 2.640
- 2.244
- 2.221
- 2.192
- 2.169
- 2.138
- 2.111
- 2.086
- 2.056
- 1.381
- 1.062
- 1.037







26




7.270
 7.081
 7.052
 7.023
 6.996
 6.971
 6.772
 6.756
 6.746
 6.724
 6.717
 6.708
 6.542
 6.539
 6.535
 6.517
 6.514
 6.510
 5.538
 5.488
 5.031
 4.981
 3.767
 3.733
 3.346
 3.310
 3.299
 3.262
 2.928
 2.892
 2.856
 2.715
 2.690
 2.458
 2.434
 2.421
 2.410
 2.397
 2.385
 2.349
 2.324
 2.307
 2.299
 2.281
 1.701
 1.674
 1.665
 1.660
 1.637
 1.632
 1.626
 1.594
 1.512
 1.115
 1.091





28






28







20b


- 1.495
- 1.590
- 1.719
- 1.912
- 2.337
- 3.756
- 4.855
- 4.809
- 4.571
- 4.526
- 6.099
- 6.152
- 6.704
- 6.726
- 6.732
- 7.039
- 7.068
- 7.142
- 7.195
- 7.210
- 7.257
- 7.270







20b







20d








24





24

